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ABSTRACT OF DISSERTATION

COMPUTATIONAL MODELING GUIDED DISCOVERY OF NOVEL INHIBITORS
OF MPGES-1 AND BUTYRYLCHOLINESTERASE AS DRUG CANDIDATES
Ever since the advent of computer-aided drug design (CADD), in silico simulation
methods have greatly accelerated the drug discovery process and lead to the discovery of
numerous drug candidates. With the exponential growth of computational power, we
nowadays simulate biologic systems at a scale unimaginable a decade ago and thus
provides perspectives for drug design. In this dissertation research, combining in silico
simulation methods like molecular docking and molecular dynamics (MD) simulation with
organic synthesis, in vitro/in vivo experiments and clinical data mining, we developed new
drug discovery strategies. These strategies were applied in our drug discovery projects and
led to the discovery of inhibitors of microsomal prostaglandin E2 synthase 1 (mPGES-1)
and butyrylcholinesterase (BChE) as potential drug candidates.
Protein mPGES-1 is known as an ideal target for next generation of anti-inflammatory
drugs without the side-effects of currently available anti-inflammatory drugs.
Unfortunately, almost all the previously reported human mPGES-1 inhibitors are inactive
(or possess very low activity) against mouse or rat mPGES-1 that prevents using wellestablished mouse/rat models of inflammation, pain, and other diseases for preclinical
studies. It would be extremely challenging for the mPGES-1-based drug development to
follow traditional drug discovery and development route. In order to solve this problem,
we developed and applied Drug Repurposing Effort Applying Integrated Modeling-in
vitro/vivo-Clinical Data Mining (DREAM-in-CDM) strategy in this project. With
molecular dynamics simulation, we observed the process of how mPGES-1 adopts an
alternative conformation to control the access of co-factor GSH (glutathione) and its impact
on the function of the protein. Based on the simulation results, we not only found an
explanation for the difference between the X-ray and CryoEM (cryogenic electron
microscopy) structure of mPGES-1 but also used molecular docking method to identify
FDA approved drug, lapatinib, as an mPGES-1 inhibitor by virtual screening and the
subsequent in vitro experiments. By mining the available clinical trial data, we found solid
evidence that lapatinib can be used to relieve various types of pain in cancer patients. Since
lapatinib is very well tolerated, we expect lapatinib to be repurposed as a new treatment for
cancer-related pain.
BChE has been identified as an ideal drug target for the treatment of Alzheimer’s
disease (AD) and heroin overdose. The selectivity of a therapeutically useful inhibitor for

BChE over AChE is very important. Unfortunately, there is no good selective BChE
inhibitor. With a robust and virtual screening strategy combining with in vitro experiments,
we identified a series of compounds from the NCI compound depository as BChE
inhibitors with novel scaffolds, high activity and selectivity at the same time. The most
potent compound was re-synthesized and the enantiomers of the compound were separated
for the first time. The binding mode of the most potent compound was also analyzed and
the origin of its high activity and selectivity was revealed that will guide the development
of BChE selective inhibitors in the future. In addition, a new tacrine-based BChE affinity
chromatography resin was developed. The developed new resin has enabled us to more
conveniently and efficiently purify the BChE proteins with improved high purity.
In general, we have successfully developed new drug discovery strategies to identify
novel inhibitors of different enzymes. With these newly developed strategies, we expect
additional drug discoveries to be made in the foreseeable future.
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CHAPTER 1. A BRIEF INTRODUCTION OF IN SILICO SIMULATION METHODS.

With the exponential growth of computational power, in silico simulation methods
now play an increasingly important role in drug discovery and development. For more than
three decades, in silico simulation has become one of the most useful tools for new
chemical entity discovery. The drugs discovered using in silico simulation methods like
saquinavir and imatinib served the market for many years and helped millions of patients
improved their lives.1-2 Among all the in silico simulation methods, there are two methods,
namely molecular docking and molecular dynamics (MD) simulation, that are more
extensively used than other methods and have played crucial roles in drug discovery. This
chapter will provide a brief introduction to these two methods.

1.1

MOLECULAR DOCKING
A molecular docking process serves two main purposes: the first one is to predict the

binding pose of a ligand molecule to its receptor, and the second one is to evaluate the
binding affinity of the ligand to its receptor based on the predicted binding pose. As a result,
molecular docking is a crucial part of virtual screening. To achieve these goals, two main
modules are involved in a molecular docking package, namely a scoring function for the
evaluation of binding mode of the ligand, and a binding-pose search engine to determine
which binding-pose yields the best binding score.
A scoring function is used to evaluate the binding affinity of a ligand to its receptor,
and in the early days of molecular docking, physics-based scoring functions3 were used
because they are intuitive and easy to implement. However, a physics-based scoring
function is usually computationally expensive and defies the main purpose of molecular
docking that needs to be time-efficient in virtual screening. Besides, despite the positive
features, the accuracy of these physics-based scoring functions was far from satisfying.4
As a result, other types of scoring functions, like empirical-based scoring functions5 and
knowledge-based scoring functions,4,

6

were also developed. These types of scoring

function were less computationally expensive and had higher accuracy in calculating the
binding affinity. Hybrid scoring functions containing features from both empirical
functions and force-field based scoring functions were also developed to balance the needs
1

for computational power and accuracy.7 With the growth of computational power,
machine-learning based scoring functions were also developed that had unprecedented,
high accuracy and had less complexity for less computational time consumption.8 The main
drawback of the machine-learning based functions, as well as some empirical based
functions is that the terms in these functions had no physical meaning in the real world and
functioned as “black boxes”. Some examples of typical scoring functions are showed below
in Figure 1.1.

Figure 1.1 Examples of scoring functions used in molecular docking software. (A) A forcefield based scoring function, used in UCSF DOCK.9 A and B: Van der Waals parameters;
r: distances; q: atomic charge; ε: dielectric constant. (B) A knowledge based scoring
function DrugScoreCSD.10 Ei,j: specific interactions energy between atoms of type i and j;
r: distances; ij: total number of types of atom interactions. N: occurrence frequencies N of
atom pairs with types i and j. (C) An empirical based scoring function, used in Autodock
Vina.5 w: weight; Ehb : hydrogen bond term; Ehp: hydrophobic term; Erp : repulsion term;
Egauss1 and Egauss2(d): Gaussian terms; Erb: rotatable bond term. For the detailed definition
of each term, please find them in the references.5
As the scoring function determines the accuracy of a molecular docking process, a
search engine determines how fast each docking process can be constructed and evaluated.
With at least six degrees of freedom on the ligand and variable complexities of the scoring
functions, searching for the optimum binding pose is at least a NP(non-polynomial)-hard
problem.11 Many searching algorithms like Monte Carlo12 and genetic algorithm3 were
applied to approach the local minima. As computational power increased, we can now
sample a much larger chemical space than ever before and the success rate of locating the
global minimum reaches as high as 90%.13 However, when performing virtual screening,
rigid-ligand docking is usually not applicable because most compounds in a library have
more than one rotatable bond.13 To determine the correct binding conformation of these

2

compounds, increased degrees of freedom are taken into consideration to make these bonds
freely rotatable at all dihedral angles, and thus the searching time grows exponentially. As
a result, a robust, search algorithm is crucial to make the computational time acceptable
and to locate a reasonable binding pose of the ligand.
There are many different algorithms applied in different molecular docking programs
and the efficiency of these algorithms vary greatly. In addition, different scoring functions
have various performances on different target proteins, and thus, there is no single best
algorithm for all the different scoring functions.10 As a result, it is important to perform redocking experiments to find out what types of algorithms fit the target system best before
we perform large scale virtual screening.

1.2

MOLECULAR DYNAMICS (MD) SIMULATION
While molecular docking is used to find the minimum energy state of a system, the

main purpose of molecular dynamics is to simulate the motions of the system based on
physical rules. At the beginning of a MD simulation, a set of coordinates of for particles in
the system and velocities for these particles are given. Just like the force-field based scoring
function used in molecular docking, a potential energy function will be used to calculate
the forces applied on the particles in the system. These forces can be used to update the
coordinates and velocities of the particles in the system for the chosen time-step in a MD
simulation based on Newtonian mechanics. (Quantum mechanics can also be applied, but
since the calculation involving quantum mechanics are complicated and time consuming,
its application in MD is still limited.) This process can be repeated endlessly until the predetermined total simulation time is reached. A flowchart of a molecular dynamics process
is shown in Figure 1.2.
Since MD is focused on the motion of a system, it can be used to evaluate many
properties of a protein that are not currently observable in experiments. For example, by
X-ray crystallography we observe a protein at its minimum energy state, and yet most
proteins alter their conformations in solution to achieve their biological functions.
Experimental methods like nuclear magnetic resonance (NMR) provide some information
about the relative relationships of some atoms in the system but the NMR experiment itself
is complicated and the data analysis remains difficult for large proteins. With the help of
3

MD simulation, however, we can not only sample multiple possible conformations of a
protein, but also, we observe the whole dynamic process of how a protein changes its
conformation. With a clear picture of protein conformational changes, we can target a
protein at alternative conformations rather than only focused on one energy minimum state.
This provides us new perspectives in drug discovery. Besides, MD simulation can also be
used to calculate free energy differences between similar states. This method has been
widely used nowadays in drug discovery to evaluate the binding energy of the ligand to its
receptor that is complementary to the molecular docking method.14

Repeat until predefined t was reached
Figure 1.2 A simplified description of the standard molecular dynamics simulation
algorithm. r: coordinates of the atom; v: velocity of atom. a: acceleration. Original author:
Knordlun.
License:
CC
BY-SA
3.0.
Link:
https://en.wikipedia.org/wiki/Molecular_dynamics#/media/File:Molecular_dynamics_alg
orithm.png

4

This brief introduction to molecular docking and molecular dynamics simulation
provides only a glimpse of these methods. In depth details of these methods are beyond the
scope of this dissertation, but in this dissertation will describe the application of these two
basic simulation methods, combined with other methods, like data mining and wet lab
experiments, to develop new drug discovery strategies. In the following two chapters, I
will demonstrate how the new strategies were deployed in two different discovery projects
and how they led to the identification of drug candidates.

5

CHAPTER 2. COMPUTER AIDED DISCOVERY OF NOVEL MPGES-1 INHIBITORS WITH NEW
ACTING MECHANISM

2.1

INTRODUCTION: A
DRUGS (NSAID)

BRIEF HISTORY OF

NONSTEROIDAL

ANTI-INFLAMMATORY

Inflammation is more of a collection of symptoms than of a specific disease. It is a
necessary part of our innate immune system, and it helps protect us from infectious
invaders. However, this self-protection mechanism will often cause unnecessary sideeffects such as excessive pain and sometimes even worse cases such as rheumatoid arthritis
or other autoimmune diseases.15 As a result, inflammation represents a target for treatment
throughout the human history.
Roughly a dozen decades ago, aspirin was synthesized, and it remains one of the
greatest discoveries in pharmaceutical history16. Aspirin is used for many different
indications nowadays， but it is still most widely used as an NSAID.17-21 Following the
discovery of aspirin came the invention of ibuprofen and naproxen and many other first
generation NSAIDs. All these first generation NSAIDs greatly relieved pain in modern
human society and were easily available over-the-counter all around the world.
Unfortunately, these convenient compounds come with some undesired side-effects.
Taking aspirin, for example, may lead to gastrointestinal bleeding and thus cannot be taken
by patients with hemophilia or patients taking warfarin.22-24 In worst cases, it may also lead
to aspirin-induced asthma.25-26
The detailed mechanism describing how aspirin works, however, was not elucidated
until 1971 by J. R. Vane et. al.27-29 For this work he was later awarded the 1982 Nobel
Prize in Physiology or Medicine together with S. K. Bergstrom and B. I. Samuelsson for
their discovery on prostaglandins.30 Aspirin was determined to be an inhibitor of
cyclooxygenase (COX). COX was the crucial enzyme responsible for the synthesis of
prostaglandin G2 (PGG2) and prostaglandin H2 (PGH2) that are the precursors of the
bioactive prostaglandins.
Among the numerous downstream prostaglandins, only PGE2 plays a key role in
inflammation. The other prostaglandins have their own physiological effects and are not
directly linked to inflammation. For example, prostaglandin I2 is important in protecting

the gastrointestinal mucosa;31 prostaglandin D2 causes the contraction of muscles; and
thromboxane facilitates the platelet aggregation.32
COX has three isoenzymes, but only COX-2 is over-expressed in inflammation tissues.
Thus, discovery of COX-2 specific inhibitors (coxib) became an important topic.33-36 In
1990s, many coxib drugs developed were selective inhibitors that specifically antagonize
COX-2, which is involved in the biosynthesis of PGE2. By selectively inhibiting COX-2,
fewer side-effects were reported than were expected,37 and these COX-2 inhibitor soon
became the best-selling drugs on market. However, these COX-2 inhibitors also had severe
potential cardiovascular side-effects,38 and one of the drugs, Vioxx, was eventually
withdrawn from market and Merck offered $4.85 billion compensation for the customers
who suffered from taking this drug.39

Figure 2.1 Pathways in biosynthesis of eicosanoids from arachidonic acid. Protein mPGES1 is highlighted in red circle. Original author: Jfdwolff. License: CC BY-SA 3.0. Link:
https://en.wikipedia.org/wiki/Eicosanoid#/media/File:Eicosanoid_synthesis.svg
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In 1999, mPGES-1 was first identified as the microsomal glutathione transferase-1 like
protein 1 (mGST1-L1) and was later renamed PGE2 synthase.40 This enzyme is specifically
responsible for the synthesis of PGE2 in inflamed tissues, which is located at the
downstream of COX-2.33, 41-44 (Figure 2.1) mPGES-1 gene knock-out mice did not have
any significant negative impacts on their normal life-spans and the inflammatory responses
were largely reduced.41-42, 45 It is reasonable to anticipate that mPGES-1 inhibitors would
suppress the common inflammatory responses while not causing the side-effects seen with
COX-2 inhibitors.46 As a consequence, mPGES-1 inhibitors could also be used to treat pain
associated with cancer,47-49 arthritis,50 pyresis,51 multiple sclerosis52 or even Alzheimer’s
disease.53 As a result, developing new mPGES-1 inhibitors as the next-generation NSAIDs
has attracted great interest.

2.2

STRUCTURAL FEATURES OF MPGES-1
To design an improved inhibitor of mPGES-1, a thorough comprehension of the

enzyme’s structure is necessary. Protein mPGES-1 is a member of the MembraneAssociated Proteins in Eicosanoid and Glutathione (GSH) metabolism (MAPEG) family5455

. Despite not having very high sequence identity within the family, all the MAPEG

members share the same tertiary structure and act as a homotrimer buried in membrane
lipid bilayers. Just like other members in the family (excluding 5-lipoxygenase activating
protein (FLAP)), mPGES-1 also has a co-factor GSH at the catalytic site, and it was
experimentally confirmed that GSH is indispensable for the catalytic activity.

8

Figure 2.2 Structure of mPGES-1 and its location in membrane. The protein mPGES-1 is
shown in yellow cartoon and the GSH co-factor is shown in ball model. The membrane
bilayer is shown in transparent green sticks.
It is usually difficult to obtain a crystal structure of a membrane protein like mPGES1. In 2013, Sjogren et. al.56 and Weinert et al.57 reported high-resolution X-ray crystal
structures of mPGES-1that displayed significant structural differences from the earlier
CryoEM structure reported in 2008.58 Since there are major differences between the
CryoEM and X-ray crystal structures, it was suggested that mPGES-1 might adopt a
different conformation in solution.56 In particular, all available X-ray crystal structures
exist in a closed conformation with GSH completely trapped inside the active site cavity.
In this conformation, GSH cannot enter or leave the active site cavity without a major
conformational change of the enzyme. In this thesis, the open-conformation of mPGES-1
refers to one in which both PGH2 and GSH can freely enter or leave the active site cavity.
Notably, the role of GSH in mPGES-1 is two-fold: GSH mainly serves as a co-factor for
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mPGES-1-catalyzed reaction of PGH2 to produce PGE2. In addition, GSH serves as a
substrate59 for another type of physiologically irrelevant reaction that occurs only in certain
in vitro conditions.
Previous computational modeling60 of the mPGES-1 conformation started from the
CryoEM structure that had a comparatively low resolution – 3.5 Å in-plane (x-y plane)
resolution and 10 Å z-axis resolution (PDB: 3DWW).61 This modeling examined the
PGH2-binding site without examining whether the GSH-binding site was open or not. To
the best of our knowledge, there has been no report of an X-ray crystal structure of mPGES1 with the open-conformation in terms of the GSH-binding site or computational modeling
of an open-conformation of mPGES-1 starting from a high-resolution X-ray crystal
structure.

Figure 2.3 Isomerization of PGH2 by normal mPGES-1 compared with the reduction of
PGH2 by mutated mPGES-1.
It was also interesting that when R126 or D49 of mPGES-1 was mutated, the mutation
might “compromises PGE2 synthase activity, but allow PGE2 reduction to PGF2α”.62-63
How these mutations change mPGES-1 from an isomerase into a reductase is interesting
because for the reduction of PGH2 requires at least two molecules of GSH is required but
the catalytic site of mPGES-1 cannot accommodate another GSH. Since there are still many
unsolved mysteries surrounding mPGES-1, we speculate that there should be an alternative
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conformational state of mPGES-1 that may explain some of its unexpected properties. We
decided to carry out a MD simulation on mPGES-1.

2.3

MD SIMULATION OF MPGES-1 WITH AND WITHOUT GSH IN MEMBRANE.

2.3.1

Methods

Our computational modeling and simulations started from the X-ray crystal structure56 of
human mPGES-1 (PDB 4AL0 with high resolution at 1.2 Å). The mPGES-1 protein (trimer)
structure was simulated in the presence of a phospholipid bilayer of 1,2-dioleoyl-snglycero-3-phosphocholine (DOPC) and a water box in all of the MD simulations. The
CHARMM-GUI membrane builder64 was used to build the initial 3D structural model and
prepare input files for the MD simulations. Only the protein part with/without GSH of the
X-ray crystal structure was used in building the initial model. A total of 153 DOPC
molecules were used to build the membrane model, and a total of 11,365 water molecules
were added to fill the water box. In addition, 25 sodium and 46 chloride ions were added
to achieve neutrality of the system and we adjusted the salt concentration to 0.15 M. For
the LeuT (Bacterial Leucine Transporter) MD simulation, the in-membrane LeuT structure
started from the X-ray crystal structures of LeuT in the outward-occluded conformation
(PDB ID: 2A65). We used the same computational procedure used to simulate the inmembrane structure of mPGES-1. The initial LeuT structure and the MD input files were
also prepared with the same procedure used for mPGES-1. A total of 192 DOPC molecules
were used to build the membrane model, and a total of 15,450 water. molecules were added
to fill the water box. In addition, 41 sodium ions and 44 chloride ions were added to achieve
neutrality of the system and we adjusted the salt concentration to 0.15 M.
The NAMD 2.10 program65 was used to run the MD simulation for 100 ns. The input
files were generated by the CHARMM-GUI builder, and the CHARMM force field was
used in the MD simulation. The simulation temperature was set at 303.15 °K and the time
step used was 2 fs. The Nose-Hoover Langevin piston pressure control was used to keep
the temperature and pressure constant.
The AMBER12 software66 was used for the targeted MD (TMD), potential of mean
force (PMF), and Molecular Mechanics (MM)-Poisson-Boltzmann Surface Area (MM11

PBSA) simulations/calculations. Input models were generated by using the NAMD
simulation results. AMBER ff03 force field and lipid11 force field were used for the
simulation. In the TMD simulation, the closed conformation was used as the starting
conformation, and the open-conformation state was used as the final conformation. Along
the reaction coordinate, a conformation in every 5 degrees was selected as a window. For
each window, the structure was energy-minimized and equilibrated, followed by an MD
simulation (1 ns) for the conformational sampling. The obtained energetic data were
submitted to the WHAM script67 for PMF calculations.

2.3.2

Results and Discussion

Conformation of mPGES-1 with GSH bound. Starting from the high-resolution X-ray
crystal structure (4AL0), we first modeled and simulated the protein structure of mPGES1 in the presence of co-factor GSH. Throughout the 100-ns MD simulation, the average
root-mean-square deviation (RMSD) was only at 1.9 Å (Figure 2.4), and the closed
conformation of the protein structure was very stable. There was no conformational change
of mPGES-1 during the MD simulation.
Spontaneous conformational opening of mPGES-1 without GSH. To examine whether
GSH induced a significant conformational change, we performed another MD simulation
on mPGES-1 in the absence of GSH but in which mPGES-1 was still in the phospholipid
bilayer and water box. In this simulation, the protein structure had an average RMSD of
2.8 Å (Figure 2.4). In particular, a small portion (F44 to D62) of the protein underwent a
major conformational change, while the remaining protein structure was still in its original
conformation (Figure 2.5).
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Figure 2.4 Structural stability of mPGES-1 in 100 ns MD simulation of mPGES-1 with and
without GSH.
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Figure 2.5 RMSD of mPGES-1 by every residue in 100 ns MD simulation of mPGES-1
without GSH
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Figure 2.6 Overall structure of mPGES-1 at open-conformation. (A) Cap domain at its
“closed” (red) and “open” (green) conformation during the MD simulation. The other part
of mPGES-1 is shown in yellow cartoon. (B) The angle ϕ was defined using center of mass
(COM) of P63-E66 (blue), P47-A50 and L51-G54 (green).
The flexible residues (from F44 to D62, Figure 2.6(A)) are located on the GSH
binding site. In the presence of GSH, this domain acts like a cap of the GSH-binding site
and prevents GSH from contacting the solvent. When this cap domain adopts a completely
different “open” conformation (“open” is defined as ϕ < 120˚. ϕ is defined in Figure
2.6(B).), the catalytic site gains direct access to cytoplasm, allowing GSH to freely enter
or leave the active site. We then performed another 10 parallel MD simulations with the
same setting at various simulation times. During these simulations, we observed the cap
opening in all 10 simulations. (Figure 2.7 and Table 2.1)
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Figure 2.7 The change of angle ϕ against simulation time in ten additional MD simulations
with same settings but various simulation times. When ϕ was less than 120˚, the cap was
considered as open. Trajectory 0 is same trajectory discussed above.
Table 2.1 The first occurrence of cap opening event observed in simulation and total
simulation times of all the MD simulations. Trajectory 0 is the one showed and discussed
in the main part of the dissertation and the cap opening process of the other 10 trajectories
are shown in Figure 2.7.
Trajectory ID

First occurrence of cap
opening event (ns)

Total simulation time (ns)

Trajectory 0

36.6

100

Trajectory 1

192.6

500

Trajectory 2

89.7

100

Trajectory 3

351.8

500

Trajectory 4

89.0

400

Trajectory 5

225.2

500

Trajectory 6

147.1

400

Trajectory 7

138.5

500

Trajectory 8

149.1

500
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Table 2.1 (continued)
Trajectory 9

52.6

100

Trajectory 10

72.3

100

The major structural difference between the open and closed conformations in the cap
domain are shown in Figure 2.8 and summarized in Table 2.2. In the simulated open
conformation, despite the conformational change and loss of a few polar interactions, new
polar interactions formed at the same time to compensate for the loss of some polar
interactions. Thus, the open-conformation is expected to be at least as stable as, or more
stable than, the closed-conformation in solution.
To validate the effectiveness of this computational method, we also applied
this method to LeuT that is known to have different conformations.68-69 Starting
from the outward-occluded state (PDB ID: 2A6569), we observed the transformation of
the protein into outward-open conformation (Figure 2.9 and Figure 2.10). This outcome
indicated that this method was an effective tool to search alternative conformations of
protein.
Table 2.2 Interaction comparison of residues on the cap domain on both closed and open
conformations
Residue

Closed conformation

Open conformation

E48

Salt bridge with R67

Side chain exposed in water

D49

Salt bridge with R126

Hydrogen bond with N46

L51

Side chain exposed in water

Side chain buried

R52

Side chain exposed in water

Hydrogen bond with Side chain
of H53

H53

Side chain exposed in water

Hydrogen bond with Side chain
of R52

Q57

Stab into water

Hydrogen bond with S61

R60

Hydrogen bond with backbone

Salt bridge with E66

oxygen of K41
E66

Side chain exposed in water
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Salt bridge with R60

Figure 2.8 Detailed interactions between residues of the cap domain on closed
conformation observed from different orientations (A, B, C panels) and open-conformation
observed from the same corresponding orientations (D, E, F panels) . Protein is showed in
yellow.
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Figure 2.9 Comparison of the MD-simulated LeuT structure with the crystal structures of
LeuT in the outward-occluded and outward-open conformational states. (A) X-ray crystal
18

structure of LeuT in the outward-occluded conformation (PDB ID: 2A65). The protein is
a cyan cartoon model. The substrate leucine is in blue space-filling model (the same below).
Key residues in the substrate binding pocket (within 4 Å of substrate leucine, namely N21,
A22, V23, G24, L25, G26, N27, V104, Y108, F253, T254, L255, S256, F259, S355, and
I359) are also depicted in space-filling model (the same below). (B) X-ray crystal structure
of LeuT in the outward-open conformation (PDB ID: 3TT1). The protein is a green cartoon
model. Substrate leucine was superimposed to its binding site. (C) The MD-simulated
outward-open structure of LeuT. The protein is a yellow cartoon model. Substrate leucine
was superimposed to its binding site. (D) The MD-simulated outward-open structure of
LeuT aligned to the X-ray crystal structure of LeuT in the outward-open conformation
(RMSD for the α-carbon atoms = 1.30 Å).

Figure 2.10 Time-dependent RMSD for the α-carbon atoms in the MD-simulated LeuT
structure compared to the outward-occluded conformation (black) and outward-open
conformation (red) during the 100-ns MD simulation.
We also evaluated the binding mode of some published mPGES-1 inhibitors (MK-886,
70

MF-6371 and compound 4b72) to see if they would bind with the open-conformation or

the closed-conformation. All these compounds showed more reasonable binding modes
with the closed-conformation compared with the open-conformation, and the binding mode
of MF-63 was in good alignment with the reported X-ray crystal structure,71 a finding that
indicated these inhibitors were not interacting with the open-conformation.
Conformational dynamics and energetics for the conformational transition. In order
to know the energetics of significant conformational changes, we performed a PMF
simulation on the conformational transition of mPGES-1 using the umbrella sampling
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method. To perform this PMF simulation, a “reaction coordinate” must be defined for the
conformational transition. Since the main part of this cap domain is an -helix, we decided
to use the angle between the vector of this -helix and the x-y plane as the reaction
coordinate. However, due to the technical restriction of the MD simulation software, the xy plane cannot be chosen as an anchor point, we instead selected the COM (center of mass)
of P63-E66 as the anchor point because it was stable during the MD simulation (Figure
2.6(B)). The COM(P63-E66)–COM(P47-A50)–COM(L51-G54) angle highly correlated
with the above-mentioned angle between the -helix and the x-y plane (Figure 2.11). This
indicated that it was reasonable to use this angle as the reaction coordinate.

ϕ vs simulation time
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Figure 2.11 The change of angle ϕ (red) against simulation time compared with the angle
between the alpha helix (colored green in Figure 2.6) and the x-y plane.
The WHAM program67 analyzed relative free energy changes along the reaction
coordinate. The results, shown in Figure 2.12, revealed two local minima: one associated
with the closed-conformation and the other with the open-conformation. The free energy
difference between these two local minima was about 0.5 kcal/mol, and the free energy
barrier was only 2.5 kcal/mol, which means that these two conformations can easily change
from one to another in solution. Further, we also performed a targeted MD (TMD)
simulation, followed by the similar PMF simulation on the mPGES-1 in the presence of
GSH. The obtained energetic data that are depicted in Figure 2.12, showed that the closed20

conformation has a much lower free energy than the open-conformation in the presence of
GSH. Based on the energetic data in Figure 2.12, the free mPGES-1 protein (without GSH)
should mainly, but not exclusively, exist in the open-conformation, whereas the protein
with GSH bound should exclusively exist in the closed-conformation. These computational
results are consistent with the fact that only the closed-conformation was observed in the
reported X-ray crystal structures with GSH bound.

Free Energy vs ϕ
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Figure 2.12 The free energy landscape along the reaction coordinate when GSH is present
(black) and absent (red).
In addition, the above computational data also predict that, in the absence of GSH,
both the open- and closed-conformations of mPGES-1 co-exist in solution, with a higher
percentage in the open-conformation. In other words, the computational simulations
predict that the GSH-free mPGES-1 structure (apo-form) in solution mainly exists in the
open-conformation observed in silico.
Overall, whether mPGES-1 mainly takes the open- or closed-conformation is
dependent on the actual concentration of GSH (denoted as [GSH]) in solution. It has been
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known that the catalytic activity of mPGES-1 is dependent on [GSH] with KM value of 0.71
mM for GSH.73

Figure 2.13 Top-down view of the electrostatic surface of mPGES-1 from the cytosolic
side of the membrane. Positive charge is colored in blue and negative charge is colored in
red.
Assuming that Kd  KM under the widely used rapid-equilibration assumption59 and
when [GSH] has a value of 0.71 mM, we may expect to have [mPGES-1-GSH] equals to
[mPGES-1], where [mPGES-1-GSH] represents the concentration of the enzyme-GSH
complex and [mPGES-1] refers to the concentration of the free enzyme without GSH.
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When [GSH] is greater than 0.71 mM, we should have [mPGES-1-GSH] greater than
[mPGES-1]. Otherwise, when [GSH] is less than 0.71 mM, we should expect [mPGES-1GSH] less than [mPGES-1]. So, at the usual GSH concentration of 1 or 2 mM for mPGES1 crystallization studies,56, 74 both the open and closed conformations are expected to coexist in solution, but majority of the mPGES-1 molecules should stay in the closed
conformation when [GSH] is greater than 0.71 mM.
Ion distribution in Apo-form mPGES-1. As shown in Figure 2.13, mPGES-1 is net
positively charged on its cytosolic side. There are 11 arginine and lysine on each monomer
chain of mPGES-1 exposed to the solvent while only 5 aspartic acid and glutamic acid are
in the same situation.

Figure 2.14 Chloride anions (green spheres) are enriched in the catalytic sites (left panels)
while sodium cations are evenly distributed in the system (right panels).
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This is not surprising, since we know that the members in the MAPEG family function
as GSH transferases and GSH is negatively charged at neutral pH. As GSH is absent in this
simulation, we assumed that chloride would occupy this vacant positively charged site. An
analysis of the trajectory of the chloride anions clearly proved this assumption to be correct.
(Figure 2.14)To quantify the stability of the chloride anions in the catalytic site, we used
the alpha carbon of N74, Y130 and I31 as the anchor atoms since these residues are stable
and located at three different sides of the catalytic site. We calculated the average distance
between the chloride anion and every anchor atom. (Figure 2.15)
It is obvious that in most of the simulation time, the catalytic site will be occupied by
one chloride atom to neutralize the excessive positive charge. However, when the cap is in
open state, the exchange of the chloride is more frequent, and the catalytic site has more
time left unoccupied.(Figure 2.15)
This finding may provide an explanation of why when D49 or R126 is mutated,
mPGES-1 will change from an isomerase into a reductase.47-48 As previously discussed,
the D49-R126 salt bridge is very important for stabilize mPGES-1 in the closedconformation. When either residue is mutated, the cap domain will be much easier to flip
into the open conformation. It is clear that two molecules of GSH are required for the
reduction of PGH2 and the GSH binding site of mPGES-1 was not big enough to fit two
GSH at once. Only in our cap-open model can provided enough room for two GSH
molecules to accommodate at the same location for the reduction process. Although a GSH
molecule is larger than a chloride ion, we can still use the behavior of the chlorides to
speculate how GSH enters and leaves the catalytic site of mPGES-1.
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Figure 2.15 Analysis of the position of chlorides during the simulation. (A) Positions of
chlorides in cavity 1 which the cap did not open during the simulation. (B) Positions of
chlorides in cavity 2 which the cap did not open during the simulation. (C) Positions of
chlorides in cavity 3 which the cap OPENED during the simulation. (D) Radial distribution
function of chlorides at the GSH binding sites. The density of chlorides was calculated by
stacking all their coordinates during the 100ns simulation. The cap domain only opened at
site 3 during the simulation.
Computational insights into mPGES-1 crystallization and X-ray crystal structures.
mPGES-1 has never been crystallized in the apo-form. As discussed above, the free energy
barrier between the open- and closed-conformations is rather low (2.5 kcal/mol) in the
absence of GSH, which means the conformational transition between the open and closed
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states is easy. Thus, the open and closed states can keep the thermodynamic equilibrium
under this condition. With this new computational insight, we re-examined the crystal
structure 4AL0 again and found that the cap domain was located on the crystal packing
interface (Figure 2.16A). The interface is a perfect match between the neighboring
mPGES-1 molecules when they all exist in the closed conformation, as seen in Figure
2.16A. When the cap opens (in the open-conformation), the crystal packing could be
interrupted in the lack of favorable, intermolecular interactions (Figure 2.16B) and, thus,
the crystal will not be able to grow. So, only the closed conformation continues with the
crystal growth, which explains why only the closed conformation has been observed in the
reported X-ray crystal structures. Based on this computational insight, it would be very
difficult to obtain an X-ray crystal structure of mPGES-1 in the open-conformation.

Figure 2.16 Crystal packing interface of mPGES-1 in (A) closed-conformation and (B)
open-conformation. The protein is showed in yellow cartoon and the cap domain is in red
color for closed-conformation and green color for open-conformation.
With a given mPGES-1 concentration, the higher the GSH concentration, the greater
the percentage of mPGES-1 molecules in the closed-conformation available for the crystal
growth and, thus, the faster the crystal grows. The crystal is not expected to grow without
a sufficiently high concentration of the closed-conformation available. This computational
insight is consistent with the previous experimental observation by Li et al.74 that the
mPGES-1 protein was unable to be crystallized in the presence of a low GSH concentration.
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According to Li et al.,74 in the presence of 1 mM GSH, the crystal started to grow initially,
but disappeared between 3 and 10 days post-setup due to the susceptibility of GSH to
oxidization.
It is well-known that GSH can be oxidized spontaneously to its dimer GSSG, with a
reaction velocity of 6.6 nM min-1 when [GSH] equals to 56 µM.75 According to the
velocity of 6.6 nM min-1 when [GSH] equals to 56 µM at the room temperature, the secondorder reaction rate constant (k2) should be 2.1×10-9 nM min-1. When k2 equals to 2.1×10-9
nM min-1, GSH should have a half-life of 8 h (at the room temperature) when [GSH] equals
to 1 mM or 16 h when [GSH] = 0.5 mM, or 32 h when [GSH] equals to 0.25 mM, etc.
Clearly, starting at 1 mM, the GSH concentration became too low after 3 days post-setup,
according to our kinetic analysis. Realizing the crystal instability due to the spontaneous
reduction in the GSH concentration, Li et al.74 increased the GSH concentration in the
protein solution to 2 mM and further supplemented the precipitant solution with GSH to
the same concentration (2 mM). Under a high concentration of GSH, Li et al. was able to
obtain a single crystal suitable for diffraction.74
Experimental observation reported by Li et al.74 is consistent with our computational
insight that only the closed-conformation of mPGES-1 permits growth of the crystal and
that GSH stabilizes the closed-conformation. Our computational insight helps to
understand better the experimental observation.

The open-state mPGES-1 model shows similarity on cap domain to the CryoEM
structure. In the previous section, we mentioned that there were important differences
between the CryoEM structure and the X-ray structure of mPGES-1. The differences
cannot be simply attributed to the low resolution of the CryoEM structure, although on the
z-axis, its resolution was only 10 Å and on the x-y plane the resolution was 3.5 Å, that is
less than the displacement of some residues on the cap domain. When we compare the
CryoEM structure with our simulated one, we found that the cap domain of both structures
was strikingly similar. (Figure 2.17) This means that the cap domain of mPGES-1 in the
CryoEM structure was likely in the open-conformation.
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It is still unknown what cause mPGES-1 to change to the open-state in the CryoEM
structure. A speculation might be that the authors used copper-based grids in their CryoEM
experiment, and the presence of copper catalyzed the oxidation of GSH to GSSG, leaving
only low GSH concentration to stabilize mPGES-1 in the closed form.

Figure 2.17 Top-down view (along the Z-axis) of mPGES-1 in (A) simulated open
conformation, (B) crystal structure 4AL0 (1.2 Å resolution) and (C) CryoEM structure
3DWW (3.5 Å resolution on the X-Y plane and up to 10 Å resolution on the Z-axis). The
protein is showed in yellow wire model and the cap domain is in blue.
Potential application of the open-state mPGES-1. Most reported mPGES-1 inhibitors
are competing with the substrate PGH2. If we can make use of this newly discovered, GSHdeficient conformation and if we found a molecule that could fit into the GSH and substrate
binding site to stabilize it, we will be able to identify new GSH competitive inhibitors.
Although this idea has been proposed elsewhere, there was no confirmation in the literature.
In our opinion, it was probably because that they did not take the alternative conformation
into consideration and directly used the apo-form of the crystal structure. We already knew
that with the closed-conformation, GSH would not have access to its binding pocket and
in that case, these designed inhibitors will also be unable to reach the site. Using our capopen conformation, we may for the first time discover a true GSH competitive inhibitor.
There are also concerns about developing a GSH competitive inhibitor. The main issue
is that GSH has very high in vivo concentration and for our activity tests, its concentration
needs to be maintained at 1 mM. However, ATP (adenosine triphosphate) also has similarly
in vivo high concentrations, and thirty years ago also, scientist thought that making an ATP
competitive kinase inhibitor was unrealistic. With all the ATP competitive kinase inhibitors
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now flooding the anti-cancer market, objections along these lines subsided. Since GSH
also has a large KM value against mPGES-1, we have confidence that if the molecule has
strong enough binding affinity with mPGES-1 in the open-conformation, it can be used to
achieve in vivo activities in animals and human beings.

2.4

IDENTIFICATION OF NEW MPGES-1 INHIBITORS.

2.4.1

Current status of mPGES-1 inhibitors

As mentioned above, considerable work was invested in the discovery of mPGES-1
inhibitors as the next-generation NSAIDs, even if a clear understanding of the enzyme was
lacking. The search started from endogenous compounds: minor modifications on PGE2
were made, but the inhibition activity was at best moderate.76 Some stable analogs of PGH2
show no inhibition at all, some only showed weak inhibition against human mPGES-1 with
10 μM IC50, while arachidonic acid and its derivatives were good mPGES-1 inhibitors with
IC50 as low as 300 nM.77 As the product of another member in the MAPEG family, LTC4
was also found to be a very strong GSH competitive inhibitor of mGST-178 but its
inhibition on mPGES-1 was weak.79
Several COX-2 inhibitors act as weak inhibitors of mPGES-1:76 celecoxib (IC50 = 22
± 3 μM), valdecoxib (IC50 = 75 ± 19 μM) and lumiracoxib (IC50 = 33 ± 4 μM), for instance.
But not all these coxibs are active against mPGES-1. Etoricoxib and rofecoxib failed to
inhibit mPGES-1 even at very high concentrations (up to 200 μM).80 MK-886 is a potent
FLAP inhibitor and a moderate human mPGES-1 inhibitor synthesized by Merck.81
Derived from MK-886, compound 1 depicted in Figure 2.18 is a specific inhibitor of
human mPGES-1 with selectivity of at least 100-fold over recombinant human mPGES-2,
TXA2 synthase, and FLAP.81 Pyrazole alkalotic acid derivatives also act as inhibitors
against human mPGES-1.82 The structural optimization of this scaffold did not lead to
obvious improvements in inhibitory activity.82
In summary, although there have been an increasing number of papers reporting
inhibitors against human mPGES-1, most of the reported mPGES-1 inhibitors have not
shown good in vivo activities. None of human mPGES-1 inhibitors has an equally potent
inhibitory activity against mouse mPGES-1, which has impeded the usage of wild-type
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mouse model in preclinical studies. Hence, no mPGES-1 inhibitor has yet proven to be
clinically useful.

Figure 2.18 Some reported mPGES-1 inhibitors (IC50 showed in μM)
There are unmet demands for novel inhibitors of mPGES-1 with new scaffolds as the
next generation of anti-inflammatory therapeutics. Based on the newly discovery openconformation mPGES-1, we developed a new strategy, which may be called DREAM-inCDM (Drug Repurposing Effort Applying Integrated Modeling-in vitro/vivo-Clinical Data
Mining), to identify an FDA-approved drug suitable for use as an effective analgesic. The
DREAM-in-CDM approach consists of three steps: (1) computational modeling to predict
which FDA-approved drugs may favorably bind with the desirable drug target (mPGES-1
in this project); (2) in vitro and/or in vivo assays to validate the computational predictions;
(3) clinical data mining to confirm the efficacy associated with the required clinical end
points for the new therapeutic indication. We applied this strategy in an effort to identify
novel mPGES-1 inhibitors that bind the open-conformation.

2.4.2

Methods

In silico simulation. Compounds that were FDA-approved drugs from the Enzo
Compound

Library

(http://www.enzolifesciences.com/BML-2843/screen-well-fda-

approved-drug-library-v2/) or Development Therapeutics Program (DTP) Release 4
compound library from NCI were virtually screened using a generally applicable protocol
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described previously.83 Briefly, the protocol includes the use of AutoDock Vina 1.1.2
software84 for a receptor-rigid molecular docking and only the top ranking conformation
of the ligand was further evaluated. For all the binding complexes, a four-step procedure,
including 2,000 steps of energy minimization, 20 ps of MD simulation, 4,000 steps of
energy-minimization and the MM-PBSA method85 for estimating the binding free energies
that is similar to the known binding estimation after refinement (BEAR)86-87 protocol. The
compounds were ranked by the estimated binding free energies and screened by the PAINS
filter, and the ones with the highest ranking were first manually checked to remove the
ones with clearly unreasonable ligand conformations before they were ordered for in vitro
activity tests. The drugs with known, severe, side-effects which were not suitable to be
repurposed as an anti-inflammatory drug were also excluded.
In vitro activity assays. The protocol for the protein preparation and in vitro activity assays
were the same as described previously in our publications.59, 88-90 All compounds among
the FDA-approved drugs from the Enzo Compound Library were provided with a purity of
95% or better.91 The enzyme activity assays were performed on ice in 1.5 mL microfuge
tubes by using the expressed human or mouse mPGES-1. The reaction mixture contained:
0.2 M Na2HPO4/NaH2PO4, pH 7.2, 10 µL; 0.1 M GSH, 2.5 µL; diluted microsomal enzyme
(80 µg/mL), 1 µL; PGH2 (0.31 mM in DMF), 5 µL; 1 µL inhibitor; and H2O in a final
reaction volume of 100 µL. PGH2 was stored in dry ice and used to initiate the reaction.
Compounds were incubated with the enzyme for 15 min at room temperature before the
addition of cold PGH2 (1 µM final) to initiate the enzyme reaction. After 30 s, 10 µL of
SnCl2 (40 mg/mL) in ethanol was added to stop the reaction. The non-enzymatic
conversion of PGH2 to PGE2 was performed in the same buffer devoid of enzyme. The
reaction mixture was placed on ice until PGE2 production was determined by the PGE2
enzyme immunoassay as described earlier. IC50 values of the inhibitors were calculated by
using the GraphPad Prism 6.0.
In vivo activity tests. For in vivo tests, additional lapatinib sample (10 g at a purity of >99%
by HPLC) was ordered from LC laboratories (Woburn, MA). The air-pouch model of
inflammation92-93 is widely used for determining the in vivo effectiveness of inhibitors of
prostaglandin synthesis. Air pouches were produced by duplicate injections of 3 mL of
sterile air under the skin on the back of mice. After the formation of the air-pouch, a single
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injection of the inflammatory agent, carrageenan, into the pouch resulted in the recruitment
of inflammatory cells and the production of a fluid exudate containing significant levels of
PGE2 (an inflammatory marker) produced primarily by activities of COX-2 and mPGES1. The mice were treated po (oral gavage) with a single dose of lapatinib, celecoxib, or
vehicle for 24 h prior to collection of air-pouch fluid samples. The air-pouch fluid samples
were analyzed for PGE2 by the same ELISA method used in the in vitro enzyme activity
assay mentioned above.
Statistical analysis. GraphPad Prism 7 software (GraphPad Software, La Jolla, CA) was
used to perform the one-way analysis of variance (ANOVA) with post hoc testing, allowing
us to examine the significance of the difference in the in vivo activity data between each
pair of dose conditions. p < 0.05 was considered statistically significant.

2.4.3

Results and discussion

Based on the virtual screening results, a total of 18 FDA-approved drugs and 20
compounds from the Development Therapeutics Program (DTP) Release 4 compound
library from NCI were predicted to be inhibitors of mPGES-1. We ordered compounds
from these sources and had the in vitro human mPGES-1 activity determined with the help
of collaborator Dr. Ziyuan Zhou. The in vitro activities of the NCI compounds are listed
below in Table 2.3 and the activities of the FDA approved drugs are listed in Table 2.4.

Table 2.3 mPGES-1 inhibition activities of the compounds from NCI library at 1µM
Compound ID
1
2
3
4
5
6
7
8
9
10
11

NCI ID
95171
120921
170065
54799
149052
67373
89438
128309
38213
54689
135096

Inhibition of human mPGES-1 at 1µM (%)
62.3
52.0
42.3
38.7
29.7
27.4
23.4
23.2
16.7
14.5
13.1
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Table 2.3 (continued)
12
13
14
15
16
17
18
19
20

69290
89760
88000
71508
12461
111847
89480
53118
12849

12.1
11.5
11.0
9.3
6.0
5.0
2.9
2.5
1.5

Table 2.4 The FDA-approved drugs selected for virtual screening and tested for their in
vitro inhibitory activity against human mPGES-1.
Compound Name
Lapatinib Ditosylate
Acitretin
Calcipotriene
Ceftriaxone
Trandolapril
Aztreonam
Tolvaptan
Cefpodoxime Proxetil
Prednisolone
Cefotetan Disodium
Dipyridamole
Penicillin V Potassium
Estramustine Phosphate
Alfuzosin
Doxazosin
Adefovir Dipivoxil
Alprostadil
Dinoprostone

Inhibition (%) at 10 µM
99
83
68
57
54
53
52
47
44
44
36
36
36
22
21
19
11
4

IC50 (µM)
0.8 ±0.1
3.5 ±1.6
3.0 ±1.1
7.2 ±2.4
9.0 ±2.3
11.4 ±1.1
10.2 ±2.5
29.7 ±6.3
12.6 ±1.6
13.5 ±4.0

As shown in Table 2.3 and Figure 2.19, several compounds from NCI library were
tested with mPGES-1 and possessed in vitro inhibitory activities. Compound 1 (NCI 95171)
and compound 2 (NCI 120921) from NCI library were identified as the best “hit”
compounds with IC50 values of 367 nM and 841 nM respectively. However, these
compounds were too hydrophobic to warrant further study. The most exciting discovery
came from the FDA approved drugs. According to the initial single-concentration (at 10
µM) screening, the 18 drugs inhibited the mPGES-1 activity by 4% to 99%, and 10 out of
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the 18 drugs at 10 µM inhibited the mPGES-1 activity by at 44% or more. The “top-10”
drugs were assayed further for their IC50 values (see Table 2.4), and lapatinib was the most
potent one (IC50 = 0.8 µM or 800 nM). In addition, other FDA-approved drugs also
significantly inhibited human mPGES-1 but with relatively higher IC50 values (lower
potency). We first focused on lapatinib in further experimental tests in this investigation.

Figure 2.19 Identified mPGES-1 inhibitors from NCI library. (A) Molecular structures of
compounds 1 and 2 from NCI library. (B) Dose-dependent inhibition of human mPGES-1
by compound 1. (C) Dose-dependent inhibition of human mPGES-1 by compound 2. (D)
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Binding structure of compound 1 with human mPGES-1. (E) Binding structure of
compound 2 with human mPGES-1.
Depicted in Figure 2.20 are the computationally modeled protein-lapatinib binding
structure and in vitro activity data obtained for lapatinib. In particular, as seen in Figure
2.20 (D), lapatinib indeed competes with co-factor GSH, which is consistent with the
computationally modeled binding mode in which lapatinib occupies the GSH-binding site.

Figure 2.20 (A) Chemical structure of lapatinib. (B) Modelled binding structure of lapatinib
(cyan sticks) with mPGES-1 (yellow cartoon). The cap domain is colored in green and
some key residues interacting with lapatinib are shown in sticks. Hydrogen bonds are
shown in black dashed lines. (C) Dose-dependent inhibition of lapatinib against mPGES1. (D) Inhibition of mPGES-1 with lapatinib at constant 1 µM concentration and GSH at
different concentrations, showing that lapatinib is a GSH-competitive inhibitor.
Further, we determined in vitro inhibitory activity of lapatinib against mouse mPGES1 and obtained that IC50 = 12 µM. So, lapatinib has a 15-fold lower inhibitory activity
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against mouse mPGES-1 compared to human mPGES-1 (IC50 = 0.8 µM).

In vivo anti-inflammatory activity in mice. To examine the anti-inflammatory potential
of lapatinib, we determined the in vivo effectiveness of lapatinib using the most popularly
used mouse air-pouch model of inflammation in comparison with celecoxib (a positive
control). According to the in vivo data depicted in Figure 2.21, lapatinib significantly and
dose-dependently decreased the air-pouch PGE2 level in carrageenan-treated mice. In
comparison with the positive control (celecoxib) at a dose of 50 mg/kg (po), lapatinib at 50
mg/kg (po) is less effective, as expected. Interestingly, there was no significant difference
in the in vivo potency between 100 mg/kg lapatinib (po) and 50 mg/kg celecoxib (po), as
showed in Figure 2.21.

Figure 2.21 Data from in vivo assays using the mouse air-pouch model (n=5 for each group)
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with lapatinib or celecoxib given po. The air-pouch fluid collected from mice was analyzed
by ELISA assay for the PGE2 concentrations. GraphPad Prism 6 software (GraphPad
Software, La Jolla, CA) was used to perform the one-way analysis of variance (ANOVA)
with post hoc tests.
One can estimate the human equivalent dose (HED) associated with the highly
effective mouse dose of 100 mg/kg by using the commonly used practice guide94 for dose
conversion between different species:
𝐷𝑎𝑛𝑖𝑚𝑎𝑙
) = 𝐷𝑚𝑜𝑢𝑠𝑒 /12.3
𝐻𝐸𝐷 = (
𝐾𝑎𝑛𝑖𝑚𝑎𝑙
Equation 1
in which Kanimal is the correction factor (which is 12.3 for mouse) when the compound is
equally potent against the human and animal target proteins. In consideration of the species
difference in the in vitro potency, Equation 1 can be extended in this study as the following:
𝐻𝐸𝐷 = (𝐷𝑚𝑜𝑢𝑠𝑒 /12.3) × 𝐼𝐶50 (ℎ𝑢𝑚𝑎𝑛 𝑚𝑃𝐺𝐸𝑆 − 1)/(𝐼𝐶50 (𝑚𝑜𝑢𝑠𝑒 𝑚𝑃𝐺𝐸𝑆 − 1))
Equation 2
According to Equation 2, one can estimate the HED associated with the mouse dose of
100 mg/kg: HED = (100/12.3) × (0.8/12) = ~0.54 mg/kg (or about 35 mg per dose for
human with an average body weight of 65 kg). Although lapatinib may have some side
effects, it was reported that lower the dose used in clinical trial can reduce the occurrence
of these side effects.95 The in vivo data and the effective HED estimate suggest that
lapatinib may serve as an effective anti-inflammatory drug to treat inflammation-related
diseases for humans.
Table 2.5 Cmax (µM) of lapatinib in human plasma from clinical pharmacokinetic data and
the predicted Cmax (µM) in various human organs associated with various doses.

Dose

Cmax (µM)
in plasma

10 mg

0.019a

Predicted Cmax (µM) in various organse
Brain Heart
Lung Kidney Intestine Liver
0.002 0.041
0.311
0.201
0.100
0.002

25 mg

0.040a

0.004

0.085

0.649

0.420

0.210

0.005

50 mg

a

0.012

0.267

2.037

1.319

0.658

0.015

a

0.021

0.458

3.500

2.266

1.131

0.026

100 mg

0.124
0.213
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Table 2.5 (continued)
175 mg

0.380a

0.038

0.817

6.243

4.043

2.018

0.046

250 mg

0.546a

0.055

1.174

8.971

5.809

2.899

0.066

500 mg

1.756b

0.176

3.775

28.851

18.684

9.324

0.211

650 mg

b

0.224

4.812

36.770

23.812

11.884

0.269

900 mg

2.926

b

0.293

6.291

48.074

31.133

15.537

0.351

1000 mg

3.184b

0.318

6.846

52.313

33.878

16.907

0.382

1250 mg

6.060c

0.606

13.029

99.566

64.478

32.179

0.727

1500 mg

8.598d

0.860 18.486 141.265

91.483

45.655

1.032

2.238

a

Data in the row come from clinical trial by Bence et al.95 GW572016 ditosylate
monohydrate formulated in oral suspension; bData in the row come from clinical trial
EGF10004, Lapatinib (GlaxoSmithKline, Research Triangle Park, NC) was supplied
as 100-mg and 250-mg tablets for daily oral administration; cData in this row come
from clinical trial NCT00477464. Lapatinib was orally administered at 1250 mg once
daily; dData in the row come from clinical trial NCT00486954 and NCT01138046, 36
data points from 6 subgroups were combined for the average Cmax. Lapatinib was in 6
pills at 250 mg each once oral daily; eAll of the predicted Cmax values are calculated
based on the ratios of the drug concentrations in various organs to that in plasma in
rats reported in literature.96
Insights from clinical data mining. As an FDA-approved drug, lapatinib was tested in
clinical trials. In clinical data mining, we would like to know whether lapatinib can reach
the effective in vivo concentration in human body comparable to the IC50 value (~800 nM).
To address this question, we collected the pharmacokinetic (PK) data, particularly the
maximum drug concentration (Cmax) values, of lapatinib from five different clinical trials
and estimated the corresponding Cmax values in different tissues/organs. According to the
data collected in Table 2.5, the plasma Cmax of lapatinib in its usual dosage forms should
be well above its IC50 against human mPGES-1. In addition, the reported ratios of Cmax
values in various organs of rat to Cmax in rat plasma, along with the Cmax values in human
plasma, were used to predict the Cmax values in the corresponding organs of human
corresponding to the Cmax values in human plasma. The predicted Cmax values in various
human organs are also listed in Table 2.5. As seen in Table 2.5, lapatinib may have much
higher concentrations in various human organs compared to the corresponding
concentration in human plasma. In particular, Cmax is predicted to be as high as ~2 µM (>
IC50) in lung and ~1.3 µM (> IC50) in kidney at a dose of only 50 mg. Notably, kidney is
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rich of mPGES-1.97 All of these PK data suggest that lapatinib may serve as an effective
anti-inflammatory drug to treat inflammation and pain as well as many other informationrelated diseases.
In addition to lapatinib, we also analyzed available pharmacokinetic data obtained for
acitretin and cacipotriene because they also have low micromolar IC50 values against
human mPGES-1 (Table 2.4), but we noticed that the reported Cmax values in plasma were
all at nanomolar levels (that are much lower than the corresponding IC50 values) under the
FDA-approved dose ranges.62-64 Therefore, we concluded that acitretin and cacipotriene
would be ineffective as anti-inflammatory drugs.

2.5

META-ANALYSIS OF CLINICAL TRIAL DATA ON THE ANALGESIC EFFECTS OF
LAPATINIB

Since lapatinib showed promise to be repurposed as an anti-inflammatory drug based
on its PK data, and because there have been many clinical trials with lapatinib involved,
we realized that performing a data mining on the clinical data could provide more evidences
on the anti-inflammatory effects of lapatinib. As discussed in the introduction, pain is a
common type of inflammatory response and its occurrence was usually recorded in clinical
trials, thus analysis on the pain occurrences in lapatinib-related clinical trials may help us
determine not only its analgesic effect but also its anti-inflammatory effect. Lapatinib is an
anti-cancer drug and there was only one clinical trial studied on its analgesic effect. In 2010,
Kaufman et al. conducted a phase II clinical trial (NCT00105950) with a focus on the
quality of life accounting for many parameters, including pain symptoms in inflammatory
breast cancer patients who used lapatinib, and they concluded that lapatinib monotherapy
may “provide relief from symptoms, including pain, in the short term”.65 However, their
sample size was too small (n = 17 for the lapatinib group), thus their data was not
statistically significant (p > 0.05) in terms of the pain-relieving effects of lapatinib.65 Since
there was no related meta-analysis on the topic about lapatinib concerning its analgesic
effects and there was no existing protocol for this meta-analysis, we conducted a metaanalysis of lapatinib on its analgesic effects over various types of pain using the reported
adverse effects data.
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2.5.1

Methods

Study Searching. The primary aim of this meta-analysis was to determine the effect of
lapatinib in the pain-relieving effects in cancer patients. A comprehensive MEDLINE
database search on clinicaltrials.gov was performed to find studies using the search term
lapatinib, Tykerb or GW572016. Data concerning study design, baseline patient
characteristics, treatment and results (specifically the part of adverse effects) were
extracted from these reports.

Table 2.6 Basic information of trials analyzed in this meta-analysis
Clinical Trial #
No. of
Male, %
Patient
Mean Age,
Individuals
Type
(standard
Tolled
deviation),y
NCT0048695498
272
79
Gastric
60.5(10.2)
cancer
NCT0038712799
66
90
Head and
56.1(6.2)
neck cancer
NCT00558103100
51
0
Breast
53.0(11.3)
cancer
NCT00374322101
3147
0
Breast
52.0(9.9)
cancer
NCT00430781102
150
0
Cervical
49.5(10.9)
cancer
NCT00680901103
537
75
Gastric
58.9(11.2)
cancer
NCT00553358104
301
0
Breast
50.0(23-80)*
cancer
NCT00371566105
105
81
Head and
57.1(10.8)
neck cancer
NCT00424255106
685
83
Head and
53.8(9.1)
neck cancer
NCT00490139107
4137
0
Breast
51.0(10.2)
cancer
NCT00073528108
1278
0
Breast
63.1(9.8)
cancer
NCT00429299109
82
0
Breast
49.3(26-68)*
cancer
NCT00390455110
278
0
Breast
N/A
cancer
NCT00422903111
92
0
Breast
70(47-88)*
cancer
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Lapatinib
Dosage
1500 mg
q.d.
1500 mg
q.d.
1500 mg
q.d.
1500 mg
q.d.
1500 mg
q.d.
1500 mg
q.d.
1000 mg
q.d.
1500 mg
q.d.
1500 mg
q.d.
1000 mg
q.d.
1500 mg
q.d.
1000 mg
q.d.
1500 mg
q.d.
1500 mg
q.d.

Table 2.6 (continued)
NCT00524303112

63

0

Breast
50.4(10.0)
1000 mg
cancer
q.d.
NCT00075270113
579
0
Breast
51.8(10.7)
1500 mg
cancer
q.d.
114
NCT00770809
230
0
Breast
49.4(24-75)*
750 mg
cancer
q.d.
115
NCT00281658
443
0
Breast
49.2(10.3)
1500 mg
cancer
q.d.
*In some trials the age information was reported as mean (range). N/A: not available

Study Selection and Data Extraction. The comprehensive initial database search
identified 322 related records. Trials without adverse effects result posted or did not use
lapatinib in the experimental group were then excluded, leaving 87 studies available for
further investigation. Among the remaining trials, non-randomized trials or single-armed
trials were also removed, leaving 18 trials for final analysis (Table 2.6 and Figure 2.22).
For 16 trials the adverse effect data could be obtained from the related publications, and
for two clinical trials, the authors only published their partial results as abstracts.107, 111 For
all 18 trials the adverse effect data have been posted online. As a result, all the pain related
data were collected from clinicaltrials.gov. Since data in the “Serious adverse effects”
section across all the trials are all very small (for every kinds of pain, no one has a reported
patient count greater than 5, see Table A. 1), these data were not used in this meta-analysis.
Only data from the “Other adverse effects” section was used in this analysis.
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Figure 2.22 Flow chart for the study selection process of this meta-analysis
Statistical Analysis. R package meta 4.9-4116 was used for all the related analysis and
plotting. The Cochrane statistic and Higgins’ I2 were calculated for the assessment of
heterogeneity across the trials. Odds ratios (OR) and 95% confidence intervals (CI) of
various types of pain were calculated with both fixed and random-effects model
(DerSimonian-Laird estimator for τ2) from each data point in each study using MantelHaenszel method. The patients allocated to an intervention in a specific trial were only
compared with those in the control group of the same trial, avoiding direct comparisons of
patients across different trials with other different conditions. P value of less than .05 was
judged as statistically significant. To assess study bias, we generated funnel plots of the
logarithm of treatment effects and compared it with their standard errors for each metaanalysis.

2.5.2

Results

Search Results and Study Quality.18 randomized controlled trials were identified based
on the abovementioned criteria. 12,496 individuals were enrolled in total and all patients
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were cancer patients. Detailed demographic information appears in Table 2.6. In all these
selected trials, four were quadruple-blind;103, 108, 110-111 one was triple-blind;101 five were
double-blind;99-100,

106, 113, 115

one was single-blind105 and the others trials were not

masked.98, 102, 104, 107, 109, 112, 114 Twelve trials recruited breast cancer patients, 100-101, 104, 107115

three trials recruited head and neck cancer patients,99, 105-106 two trials recruited gastric

cancer patients98, 103 and one trial recruited cervical cancer patients.102 Three studies were
purely placebo-controlled,101, 105, 110 three studies had a paclitaxel component,98, 113, 115 four
studies had a trastuzumab component,104,

107, 109, 112

two studies had a letrozole

component,108, 111 two trial had a pazopanib component,100, 102 two trial had radiotherapy
intervention99, 106, one trial had both Paclitaxel and oxaliplatin components103 and one trial
had both paclitaxel and trastuzumab components.114 All these studies randomized about
equal numbers of individuals to lapatinib therapy and control group with the only
exceptions of NCT00371566, which used a 2:1 ratio105 and NCT00558103, which used a
3:1 ratio.100 Dosage of lapatinib ranged from 750 mg to 1500 mg daily.

Major Pain Events. Among all investigated clinical trials, 37 different kinds of pain were
complained. Most of these types of pain had a relatively small sample size when we
combined the data from different trials, making the analyses on them unreliable. As a result,
only pain types with more than 5,000 patients involved in both experimental and control
group are discussed here as the “major pain events”. There was a total of six types of pain
met this criterion, namely headache, bone pain, arthralgia, myalgia, pain in extremity and
musculoskeletal pain. The forest plots are shown below.
A total of 1,298 headache events were reported among 12,392 patients in 17 related
trials. Lapatinib was associate with 19% reduction in the odds of headache (see Figure
2.23. OR, 0.81; 95%CI, 0.70-0.93; P = .0025).
A total of 378 bone pain events occurred among 6,417 patients in 6 related trials.
Lapatinib was associate with 26% reduction in the odds of bone pain (see Figure 2.24. OR,
0.74; 95%CI, 0.60-0.92; P = .0055).
A total of 1,416 arthralgia events occurred among 11,011 patients in 13 related trials.
Lapatinib was associate with 19% reduction in the odds of arthralgia (see Figure 2.25. OR,
0.81; 95%CI, 0.69-0.95; P = .0113).
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Figure 2.23 Overall effect of lapatinib treatment on headache. Sizes of data markers are
proportional to the amount of data contributed by each trial. OR, odds ratio; CI, confidence
interval.

Figure 2.24 Overall effect of lapatinib treatment on bone pain. Sizes of data markers are
proportional to the amount of data contributed by each trial. OR, odds ratio; CI, confidence
interval.
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Figure 2.25 Overall effect of lapatinib treatment on arthralgia. Sizes of data markers
are proportional to the amount of data contributed by each trial. OR, odds ratio; CI,
confidence interval.
A total of 952 myalgia events occurred among 7,852 patients in 12 related trials.
Lapatinib was associate with 4% reduction in the odds of myalgia (see Figure 2.26. OR,
0.96; 95%CI, 0.81-1.14; P = .6625).
A total of 579 pain in extremity events occurred among 6,618 patients in 8 related
trials. Lapatinib was associate with 20% reduction in the odds of pain in extremity (see
Figure 2.27. OR, 0.80; 95%CI, 0.68-0.96; P = .0132).
A total of 428 musculoskeletal pain events occurred among 7,629 patients in 9 related
trials. Lapatinib was associate with 22% reduction in the odds of musculoskeletal pain (see
Figure 2.28. OR, 0.78; 95%CI, 0.64-0.95; P = .0137).
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Figure 2.26 Overall effect of lapatinib treatment on myalgia. Sizes of data markers are
proportional to the amount of data contributed by each trial. OR, odds ratio; CI, confidence
interval.

Figure 2.27 Overall effect of lapatinib treatment on pain in extremity. Sizes of data markers
are proportional to the amount of data contributed by each trial. OR, odds ratio; CI,
confidence interval.
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Figure 2.28 Overall effect of lapatinib treatment on musculoskeletal pain. Sizes of data
markers are proportional to the amount of data contributed by each trial. OR, odds ratio;
CI, confidence interval.
When the abovementioned data was combined, a total of 2,311 pain events were
recorded among 6,299 patients in the experimental group while there were 2,739 pain
events among 6,185 patients in the control group. We calculated the average pain event
counts in each trial and used this data to analyze the overall analgesic effect (Figure 2.29).
The result showed that lapatinib was associated with a significant 21% reduction in the
odds of the major pain events (OR, 0.79; CI, 0.69-0.89; P = .0001).For the above metaanalyses, all P values for heterogeneity were greater than 0.1 and all Higgins’ I2 values
were less than 25%, indicating no significant study heterogeneity was observed.
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Figure 2.29 Overall effect of lapatinib treatment on various kinds of pain. Sizes of data
markers are proportional to the amount of data contributed by each trial. OR, odds ratio;
CI, confidence interval.
2.5.3

Discussion

Lapatinib is an effective pain-relieving agent against various types of pain. The general
analgesic effects on various types of pain have been clearly manifested in this metaanalysis. In all the analyses we observed <1 OR values, that means lapatinib relieves these
kinds of pain in cancer patients. In five out of six analyses (headache, bone pain, arthralgia,
pain in extremity and musculoskeletal pain), the P values were <.05, which means the
reduction of OR on these types of pain are statistically significant. Both Higgins’ I2 and P
for heterogeneity showed that there was no significant heterogeneity in the trials we used
for analysis. Funnel plots (Appendix I) also showed there was no significant study bias
across these trials.
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Other factors have limited impacts on the analgesic effects of lapatinib. As listed in
Table 2.6, the trials involved in this meta-analysis are different on many factors not related
to lapatinib and they might have strong influences on the results. To check if these factors
will affect the efficacy of lapatinib, we grouped the trials in the overall effect analysis by
these other factors to investigate the impacts.
As displayed in Figure 2.30, the effects of lapatinib in the masked group (OR, 0.79;
95%CI, 0.67-0.93) was almost the same as the open label group (OR, 0.78; 95%CI, 0.650.94) with a P value of .92, indication the difference was negligible.

Figure 2.30 Overall pain relieving effect of lapatinib, grouped by the factor if the trial is
masked or not.
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Similarly, as showed in Figure 2.31, we found that the cancer type of the patient
recruited did not have a significant influence on the effects of lapatinib. For gastric cancer
patients: OR, 0.71; 95%CI, 0.27-1.89; For head and neck cancer patients: OR, 0.69; 95%CI,
0.40-1.18; For breast cancer patients: OR, 0.80; 95%CI, 0.70-0.91; For cervical cancer
patients: OR, 0.60; 95%CI, 0.20-1.77. For subgroup differences: P = .91.

Figure 2.31 Overall pain relieving effect of lapatinib, grouped by the cancer type of the
recruited patients.
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As we have discussed in the previous section, the blood concentration of lapatinib
should be well above the necessary concentration to inhibit mPGES-1 under all doses used
in these clinical trials, thus the difference should not be distinguishable. As showed in
Figure 2.32, the differences across these groups with different doses were very small (For
1500 mg/day group: OR, 0.80; 95%CI, 0.68-0.94; For 1000 mg/day group: OR, 0.77;
95%CI, 0.63-0.93; For 750 mg/day group: OR, 0.83; 95%CI, 0.36-1.94; For subgroup
differences: P = .95), which agrees with our prediction.

Figure 2.32 Overall pain relieving effect of lapatinib, grouped by the dosage of lapatinib
used in these trials.
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Although only three trials were purely placebo-controlled, in all the other trials the
additional components were present in both experimental and control group. Since the
existence of lapatinib was the only variable between the experimental and control group,
the effects of lapatinib can still be reasonably evaluated in this case. As showed in Figure
2.33, the analysis indicated that the presence of other drugs had no significant influence on
the efficacy of lapatinib in all these cases. We noticed that when paclitaxel was used,
lapatinib users had a relatively higher chance to report pain (OR, 1.14; 95%CI, 0.82-1.60),
while in all the other groups the chance was all reduced. If we compare paclitaxel using
group with the pure placebo control group (OR, 0.69; 95%CI, 0.54-0.89), the difference
was statistically significant (Figure 2.34). This phenomenon, however, was not observed
when patients are taking other drugs together with paclitaxel (When CapeOx is taken
together with paclitaxel: OR, 0.41; 95%CI, 0.16-1.09; When trastuzumab is taken together
with paclitaxel: OR, 0.83; 95%CI, 0.36-1.94). The reason of this interesting observation
cannot be easily explained, and we need more data to see if it was just caused by error due
to small sample size.
Since these three trials showed significant differences with the other trials, we tried to
remove these trials in the myalgia analysis and the new results showed that the painrelieving effects will be statistically significant (Figure 2.35. OR, 0.84; 95%CI, 0.72-0.99;
P = .0376). We also tried to remove these three trials in the analysis of other types of pain
and the statistical significances (p value) have all been improved. (Figure A1. 10 Effect of
lapatinib on headache, when NCT00075270, NCT00486954 and NCT00281658 were
excluded.)
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Figure 2.33 Overall pain relieving effect of lapatinib, grouped by the additional
components involved in these trials.
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Figure 2.34 Overall pain relieving effect of lapatinib, comparing only the group with
paclitaxel used and the pure placebo control group.

The analgesic effects of lapatinib is not related to EGFR/HER2 inhibition. Since
lapatinib is an FDA-approved drug for cancer treatment, it was possible that the analgesic
effects were caused by the inhibition of EGFR/HER2 instead of mPGES-1. We
investigated the adverse effects data from trial NCT00656136, which was a phase III trial
of another recently approved EGFR/HER2 dual inhibitor, afatinib.14 As depicted in Figure
2.36, although the sample size is small, the data showed that afatinib had no observable
analgesic effects. On the contrary, it may increase the chance of pain in extremity, which
can be reduced by lapatinib based on our previous analysis. Therefore, we believe that the
analgesic effects of lapatinib is not likely to result from the inhibition on EGFR/HER2.
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Figure 2.35 Effect of lapatinib on myalgia, when NCT00075270, NCT00486954 and
NCT00281658 were excluded.

Figure 2.36 Effect of afatinib on various types of pain. Data from NCT00656136.117
Limitations of this meta-analysis. All these trials were not originally designed to
investigate the analgesic effects, as a result the severity of the pain could not be evaluated
in these trials like the study conducted by Kaufman et al.118 A score-based clinical trial
could quantify the strength of lapatinib, guiding the best possible dosage for analgesic
effects to minimize its adverse effects. Besides, all these trials were conducted in cancer
patients, while we have proved that the analgesic effect of lapatinib is not related to its anticancer effects and it should also work similarly in non-cancer patients, we still need
additional evidence to apply to other patients as well. A new sophistically designed clinical
trial could solve these problems and manifest the true analgesic power of lapatinib.
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2.6

CONCLUSION
Through computational modeling and simulations, we have discovered an open

conformation of human mPGES-1 in solution, which is remarkably different from the
closed conformation shown in all crystal structures reported so far. The open conformation
is stable only in the absence of co-factor GSH. The newly identified open conformation
may serve a new target state for rational design of novel inhibitors of mPGES-1.
Using the computationally identified open conformation, our further virtual screening
of FDA-approved drugs, followed by in vitro and in vivo activity assays, has demonstrated
that multiple FDA-approved drugs, including lapatinib, acitretin, calcipotriene, etc., may
significantly inhibit mPGES-1. Thus, these FDA-approved drugs could also have antiinflammatory and analgesic effects, depending on their actual pharmacokinetic profiles
associated with used dosage forms.
Within all the mPGES-1 inhibitors identified from FDA-approved drugs, lapatinib is
the most potent one, with IC50 = ~800 nM. Further clinical data mining revealed that
lapatinib indeed significantly relieved a variety of pain in cancer patients when it was used
alone or in combined use with another drug in the reported clinical trials. So, lapatinib may
serve as the first highly desired non-addictive analgesic targeting mPGES-1 to treat pain
and a variety of inflammation-related diseases.
It should be noted that, so far, lapatinib has been used only for cancer patients. Hence,
further clinical trials may be required before FDA approves repurposing lapatinib as a nonaddictive analgesic to treat pain and a variety of inflammation-related diseases in noncancer patients.
Repurposing lapatinib as a non-addictive analgesic will have enormous impact on
future clinical practice, especially for those related to opioid drugs and opioid use disorders
(OUDs). In the United States, approximately 25.5 million adults suffer from chronic pain,
and opioids are often prescribed; this can lead to opioid misuse and OUDs.119 As one of
the most devastating consequences of opioid misuse, opioid overdose can produce
respiratory depression and death. Drug overdose is the leading cause of accidental death in
the United States. It has been estimated that there were over 60,000 drug overdose deaths
in 2016, including 20,101 overdose deaths related to prescription pain relievers and 12,990
overdose deaths related to heroin.120 It has also been reported that more than 2 million
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Americans suffer from OUDs, and for many their OUD began with prescribed opioids. For
example, 80% of recent heroin initiates reported that they began their opioid use through
the use of prescription opioids.121 The prevalence of prescription opioid abuse is similar
among men and women. Based on the known connection between the prescription opioid
use and opioid use disorder/overdose, it is highly desirable to have a truly effective and
safe, non-addictive pain medications that can be used as alternatives to opioids for pain
relief to prevent the initiation or progression of OUDs and prevent overdoses.
As well known, opioids are a class of analgesics with the capacity to deliver pain relief
by activating opioid receptors, particularly µ-opioid receptors. While effective as
analgesics, opioids are also associated with abuse and physical dependence potential.
Currently available opioids also have other side-effects including constipation, sexual
dysfunction and depression.122 The other major class of analgesics in clinical use
are NSAIDs that block COX-1 and/or COX-2 that are necessary for biosynthesis of PGE2,
and these are not associated with abuse potential. Unfortunately, the use of the currently
available

NSAIDs

(COX-1/2

inhibitors) have

significant

cardiovascular

and

cerebrovascular risks that have limited their utilization.123-124 Hence, within the currently
available pain medications, the choice is a dilemma: “When you consider or are prescribed
a pain medication, think about all the possible complications that could arise from
taking it. You may be risking a heart attack or stroke, or living with an addiction to (often
expensive) pain medication.”125 Therefore, it is highly desirable to develop novel, nonaddictive and safer pain medications.
We anticipate that repurposing lapatinib as a non-additive pain medication will
dramatically improve pain medication and treatment of inflammation-related diseases and
help to effectively prevent initiation or progression of OUDs and prevent opioid overdoses.
Based on the patents (US6391874, US6713485, US6727256, US6828320, US7157466)
filed by GlaxoSmithKline, the lapatinib-related patents already expired or will expire very
soon, making lapatinib generic and cost-attractive for patients with pains. Further, the
scaffold of the lapatinib structure may be used as a new starting point for future rational
design of an analog that inhibit mPGES-1 without inhibiting EGFR or HER2. Such a
lapatinib analog may serve as an improved analgesic compared to lapatinib itself in terms
of both the efficacy and side-effects. Similarly, the scaffolds of other FDA-approved drugs
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identified as mPGES-1 inhibitors (with the IC50 values listed in Table 2.4) may also be
used as new starting points for rational design of their analogs that can more potently and
selectively inhibit mPGES-1.
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CHAPTER 3. COMPUTER-GUIDED DESIGN, SYNTHESIS AND EVALUATION OF NOVEL
SELECTIVE BUTYRYLCHOLINESTERASE INHIBITORS

3.1

INTRODUCTION

Cholinesterases (ChEs) are the enzymes that hydrolyze the neurotransmitter
acetylcholine (ACh). There are two types of ChEs, namely acetylcholinesterase (AChE)
and butyrylcholinesterase (BChE), both are well-known targets for treatment of
Alzheimer’s disease (AD), the most serious neurodegenerative disease that has affected
about 30 million people.126 In a long period of time, AChE was regarded as the principle
ChE with physiological function while BChE was thought to be mainly supplemental and
trivial. However, it is recently discovered that AChE levels in progressed AD patients
decline to two thirds of the normal level127-128 while BChE level may increase 11-fold
relative to the AChE level in certain parts of the brain, a finding that suggests BChE might
play a dominant role in AD development.129-130 In 2005 Greig et al. reported that the
inhibition of BChE in rats increased the brain ACh level, lowered the number beta amyloid
plaques in brain, improved the performance of rats in learning,131 there by showed that
selective inhibition of BChE could be an attractive target for AD.
The first four drugs that were approved by the FDA for AD treatment are cholinesterase
inhibitors that either inhibited both AChE and BChE (tacrine, doneperzil, and rivastigmine)
or selectively inhibited AChE (galantamine). (Figure 3.1) However, studies reported in
recent years revealed that BChE might be a better target than AChE for the AD
treatment.132-134 In other words, a BChE-selective inhibitor may be more promising than
an AChE inhibitor for AD treatment.127-139

Figure 3.1 Chemical structures of FDA approved ChE inhibitors. In vitro activity data of
the FDA approved drugs was reported by M. Bolognesi et al.140
In addition, in a recent study reported by our laboratory,141 we proposed and validated
a new therapeutic strategy for heroin toxicity treatment by using a selective BChE inhibitor
to block heroin activation. A highly selective BChE inhibitor significantly attenuated the
heroin-induced toxicity and its physiological effects.141 Hence, it is interesting to develop
potent and highly selective BChE inhibitors in drug development for therapeutic treatment
of both AD and heroin abuse.
A variety of cholinesterase inhibitors with various scaffolds are either not sufficiently
potent for BChE142-153 or almost equally potent for both AChE and BChE.151, 154-167 For
some other BChE inhibitors, the selectivity is unknown (not tested at all).168-169 Few types
of cholinesterase inhibitors have promising potency and selectivity for BChE over
AChE.137, 143, 151, 164, 170-182 Some BChE inhibitors were also detected by virtual screening
methods but either their experimentally determined activity were mediocre183 or their
selectivities over AChE were not reported.184-185 Consequently, we sought to identify new,
highly selective and potent BChE inhibitors as options for further drug development efforts.
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Besides BChE’s potential to become a drug target, BChE itself also has potential to
become a drug. BChE is seen as a viable protection to organophosphorus poisoning, efforts
were made to use BChE as the detoxicant of organophosphorus compounds like nerve
agents such as sarin and soman,198-201 although the activity of the wild-type BChE is too
low and requires large amounts of BChE. Similarly, BChE was known to be able to
hydrolyze cocaine in vivo; unfortunately, the activity in this regard was also very low. In
our group, we designed and developed multiple of human BChE mutants and their fusion
proteins that showed significantly improved catalytic efficiency and half-life. These
mutants not only rescue acute cocaine overdose but also treat cocaine addiction.186-197

3.2

STRUCTURE-BASED

VIRTUAL

SCREENING

OF

SELECTIVE

BUTYRYLCHOLINESTERASE INHIBITORS

Many reports focused on derivatives of the FDA-approved ChE inhibitors, but we did
not find any promising BChE selective inhibitors among these compounds. As a result,
minor modifications on the scaffold of current drugs may not be sufficient to produce
satisfying results. Therefore, we decided to use virtual screening as a tool to find BChE
inhibitors with novel scaffolds. Despite sharing 52% identity and 70% similarity (Figure
3.2), the catalytic site of AChE and BChE differ in the size of the binding pocket. Because
the binding pocket of BChE is larger than that of AChE, we decided that compounds with
bulky fused rings would be preferred as potential BChE inhibitors.
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Figure 3.2 Sequence alignment between AChE and BChE.
3.2.1

Materials and methods

Structure-based virtual screening. Our virtual screening was performed on the
Development Therapeutics Program (DTP) Release 4 compound library including
~265,000

compounds

available

at

the

National

Cancer

Institute

(NCI)

(https://cactus.nci.nih.gov/download/nci/) by using the X-ray crystal structures of human
BChE (PDB entry 4BDS)202 and AChE (PDB entry 4EY5).203 During the virtual screening,
Autodock Vina 1.1.2 software84 was used to search for the optimum binding conformation
for each compound in the NCI compound library. To minimize the searching area, a 15 Å
× 15 Å × 15 Å box containing the active site of BChE or AChE was chosen as the target
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binding site. The receptor was made rigid, and all the water molecules in the original crystal
structure were removed before docking. The default settings of Autodock Vina were used,
and no other parameters were modified. The compounds were then ranked by their binding
free energies (docking score) with BChE. Within the top-ranked compounds, only the
compounds predicted not to fit the AChE active site at all (i.e., possessed a positive binding
free energy with AChE) will be selected from the NIH DTP program. All the binding
modes were investigated and visualized using PyMol.204
In vitro activity tests. The compounds selected from the virtual screening were assayed
for their inhibitory activity against BChE. Both wild-type AChE and BChE were expressed
and purified based on a previous reported protocol.205 For activity determination, we
followed the original Ellman’s protocol, as described in detail in our previous report.205
The enzyme activity assays were performed at room temperature in standard 96-well plates
by using the expressed human wide-type BChE. BChE was stored in -20˚C, and it was
diluted to 50 pM with 0.1M PBS buffer (at pH 7.4). Compounds were diluted to various
concentrations using DMSO. A reactant mixture was also prepared 10 minutes before the
enzyme reaction, which contains 100 µM of acetylthiocholine (ATC) and 100 µM of 5,5'dithiobis-(2-nitrobenzoic acid) (DTNB). The compound solutions were mixed with the
enzyme solution (1.5 µL of compound + 133.5 µL of enzyme solution) for 10 minutes at
room temperature before the addition of mixture of ATC and DTNB solution (15 µL). Final
concentrations at 10 µM were used to initiate the enzyme reaction. After the reaction was
initiated, the plate was immediately placed into a plate reader to determine the absorbance
at 410 nm. IC50 values of the inhibitors were calculated by using the GraphPad Prism 6.0.
Organic synthesis. All the chemicals used are purchased either from Sigma-Aldrich (St.
Louis, MO) or Oakwood Chemical (West Columbia, SC) without further purification. 1H
NMR and 13C NMR were recorded using a Varian 400 spectrometer in DMSO with TMS
as internal reference.
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Figure 3.3 Synthesis of 31. Reagents and conditions: (a) 2-formylpyridine, HCl ethanol
solution, 80°C, 16 h (90%); (b) PtO2, acetic acid, 4 atm. hydrogen, 18 h (40%); (c) ethanol,
80°C, 12 h. (57%)
Preparation of 1-(Pyridin-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (31-1): In a
100 mL round-bottom flask, 3.2 g (20 mmol) of tryptamine and 2.15 g (20 mmol) of
picolinaldehyde were added and 25 mL of 1.25 M HCl ethanol solution was added. The
mixture was refluxed with stirring for 16 h, and the excess ethanol and HCl were removed
under vacuum. The resulting orange crystalline powder was the hydrochloride salt of 31-1
and was used directly for the next step without further purification. Yield for 31-1 was 90%.
Preparation of Erythro-1-(piperidin-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
(31-2): In a 100 mL glass cylindrical tube, 3 g (12 mmol) of 31-1 HCl salt and 50 mL of
acetic acid were added together with 300 mg of PtO2. The mixture was connected to a
hydrogenator under 4 atm hydrogen at room temperature for 18 h. The solid in the mixture
was filtered, and the solvent was evaporated under vacuum. The remaining oil was then
dissolved in 20 mL chloroform and then basified with aqueous ammonia solution to pH 12.
The mixture was extracted with chloroform (3 × 20 mL). The extracts were dried over
potassium carbonate and evaporated and then recrystallized using ethanol. Yield of 31-2
was 40%.
Preparation of Threo-1-(piperidin-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
(31-2′): The mother liquid used in the recrystallization of 31-2 was evaporated, and the
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residue was dissolved in diethyl ether and filtered. The filtrate was cooled to 0˚C, and the
precipitate was directly used for the synthesis of 31′. Yield of 31-2′ was 4%.
Preparation

of

(±)-6-(3-Chlorophenyl)-1,3,4,8,9,14,14b,14c-octahydro-2H,6H-

pyrido[1'',2'':3',4']imidazo[1',5':1,2]pyrido[3,4-b]indole (compound 31 and 31′): In a
50-mL round bottom flask, 510 mg (2 mmol) of 31-2 and 310 mg (2.2 mmol) of 3chlorobenzaldehyde were diluted with 15 mL of absolute ethanol. The mixture was
refluxed with stirring for 16 h, and the excess solvent were removed under vacuum. The
residue was purified using silica column with a mixture of hexanes and ethyl acetate (4:1).
The final product was a white crystalline solid. Yield for 31 was 57%. Preparation of 31′
followed the same protocol with.
NMR Data for 31. 1H NMR (400 MHz, DMSO-d6) δ 10.76 (s, 1H), 7.51 (s, 1H), 7.37 (s,
4H), 7.29 (dt, J = 8.1, 1.0 Hz, 1H), 7.00 (ddd, J = 8.1, 7.0, 1.3 Hz, 1H), 6.93 (ddd, J = 7.9,
7.0, 1.1 Hz, 1H), 4.22 (d, J = 8.3 Hz, 1H), 3.92 (s, 1H), 2.79 – 2.61 (m, 3H), 2.55 – 2.44
(m, 2H), 2.27 – 2.19 (m, 1H), 1.97 (ddd, J = 10.9, 8.4, 2.4 Hz, 1H), 1.85 (td, J = 11.0, 10.6,
2.7 Hz, 1H), 1.76 (d, J = 13.3 Hz, 1H), 1.58 – 1.43 (m, 2H), 1.33 (dd, J = 12.3, 4.1 Hz, 1H),
1.21 – 1.10 (m, 1H).13C NMR (101 MHz, DMSO-d6) δ 144.18, 136.62, 135.44, 133.32,
130.33, 128.91, 128.76, 128.28, 127.05, 120.95, 118.78, 117.96, 111.52, 107.38, 84.25,
71.13, 59.21, 48.75, 43.58, 28.68, 25.04, 24.10, 18.40.
Chiral HPLC separation of 31. ChromegaChiral CC4 column was used and various
conditions were examined using a Waters 2695 HPLC system. We found out that the
mixture of 70% acetonitrile and 30% of 0.2% ammonium hydroxide aqueous solution at 1
mL/min flow rate will provide the best resolution.
Specific rotation determination of (+)-31. The specific rotation of (+)-31 was detected
using a Jasco DIP-370 digital polarimeter. (+)-O,O-Di-p-toluoyl-D-tartaric acid was used
as the reference compound. [𝛼]20
𝐷 = +124˚, c = 1 in CHCl3.
Crystallography. Single crystals of compound (+)-31 suitable for X-ray crystallographic
analysis were obtained by slow recrystallization from DMSO solution of (+)-31 in the fume
hood at room temperature. Maroon single crystals of (+)-31 were placed in dry and
degassed polyisobutene oil and mounted on a fiber loop206 and used for X-ray diffraction
analysis. Single crystal X-ray diffraction data were collected at 90.0 (2) K on a Bruker D8
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Venture diffractometer with graded-multilayer focused Mo Kα X-rays. Raw data were
integrated, scaled, merged and corrected for Lorentz-polarization effects using the APEX3
package.207 Corrections for absorption were applied using SADABS.208 The structure was
solved by direct methods209 and refinement was carried out against F2 by weighted fullmatrix least-squares.210 Hydrogen atoms were found in difference maps, but subsequently
placed at calculated positions and refined using a riding model. Non-hydrogen atoms were
refined with anisotropic displacement parameters.

Non-merohedric twinning was

diagnosed with APEX3, but later handled by TwinRotMat in Platon211 as it gave a more
complete dataset. Refinement progress was checked using Platon and by an R-tensor.212
The final model was further checked with the IUCr utility checkCIF. Atomic scattering
factors were taken from the International Tables for Crystallography.213 Crystallographic
data are collected in Table 3.4. All other details are included in the CIF, which will be
available free of charge from the CCDC, deposition code 1846390.

3.2.2

Results and discussion

Solanaceous alkaloids identified as BChE selective inhibitors. Based on the structurebased virtual screening, we selected a set of 10 compounds (21 to 30 depicted in Figure
3.4) that were predicted to bind with BChE only but not to AChE. These compounds are
natural products with solanaceous alkaloid scaffolds. The binding free energies calculated
for AChE binding with compounds 21 to 30 ranged from +4.5 kcal/mol to +17 kcal/mol;
the positive binding free energy means that the free energy of the protein-ligand complex
is higher than the total free energy of the separated protein and ligand. BChE has a
relatively larger active site cavity than AChE, and these molecules fit the BChE active site
cavity, whereas the AChE active site cavity is not large enough to accommodate them (see
below for the detailed binding structures).

66

Figure 3.4 Molecular structures of the 10 compounds with solanaceous alkaloid scaffolds
selected through virtual screening.

Next, the computationally selected compounds 21 to 30 were assayed for their
inhibitory activity against human BChE. They were assayed first for their inhibitory
activity at a concentration of 5 M. As seen in Table 3.1, these compounds at 5 M
inhibited the BChE activity by 8-100%. The top-3 compounds (21 to 23) inhibited BChE
by at least 95%. The most active compounds (21 to 23) were tested further for a dosedependent inhibition in order to determine their IC50 values (see Table 3.1. The inhibition
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curves could be found in Appendix III) against BChE. As seen in Table 3.1, we obtained
IC50 = 16.8 nM, 346 nM, and 391 nM for compounds 21 to 23, respectively.

Table 3.1 Inhibitory activity of computationally selected solanaceous alkaloids
(compounds 21 to 30) against human BChE
Compound

NCI ID

ID

Convention

Inhibition

Inhibition

IC50 against

al Name

(%) of BChE

(%) of AChE

BChE (nM)

at 5 µM

at 5 µM

21

76025

Solanidine

100

22

16.8

22

27592

Tomatidine

95

9

346

23

35543

Solasodine

98

6

391

24

734950

44

25

76026

39

26

152144

24

27

23898

22

28

7520

18

29

117607

14

30

117612

8.3

Interestingly, according to our detailed literature search, compounds 21 to 23 were
tested for their inhibitory activity against AChE by Roddick et al.,214 and they demonstrated
that none of these compounds (21 to 23) at a high concentration of 100 M had significant
inhibition against AChE. We have not found any report of testing their compounds against
BChE. Taking our new experimental data for the inhibitory activity against BChE obtained
in this study together with the inhibitory data against AChE reported earlier,214 we can
conclude that compounds 21 to 23 are indeed highly selective inhibitors of BChE without
inhibitory activity against AChE at all, an outcome that is consistent with the
aforementioned prediction from computational screening.
Depicted in Figure 3.5 are the docked binding structures of BChE with the most active
compounds (21 to 23) identified. According to the docked binding structures with BChE,
the inhibitor (compound 21, 22 or 23) resides in a hydrophobic environment but having a
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favorable hydrogen bond (HB) between the hydroxyl group of the inhibitor and the
backbone oxygen of amino-acid residue H438. The HB with compound 21 is the strongest
(with the shortest O…H distance of 1.956 Å), perhaps explaining why compound 21 the
most potent inhibitor of BChE with IC50 = 16.8 nM within these three inhibitors. With
these three inhibitors, their order of the HB strengths is consistent with their order of the
IC50 values.
Panels B, D, and F of Figure 3.5 also show why the AChE active site cavity cannot
accommodate any of these compounds. Specifically, panels A, C, and E show the docked
favorable binding structures of BChE with compounds 21, 22, and 23, respectively. The
corresponding unfavorable interactions of the compounds with AChE (after BChE is
replaced with AChE) are depicted in panels B, D, and F, respectively. For the major
differences between BChE and AChE in the protein-ligand interactions, residues Q119,
A277, and A328 in BChE are replaced with related residuals Y124, W286, and Y337,
respectively, in AChE. In the X-ray structures of AChE inhibitors,215-216 we also see that
these residues also played important roles, providing hydrophobic contacts to the
inhibitors, thus clashing with these residues could greatly impair the binding affinity of
these compounds against AChE. As a result, the compound (21 or 22 or 23) has clash with
the side chains of Y124, W286, and Y337 in AChE, explaining that these compounds
cannot bind with AChE at all, whereas they can potently bind with BChE.
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Figure 3.5 Modeled interactions of BChE and AChE with compounds 21 to 23. (A)
Favorable binding structure of compound 21 with BChE. (B) Unfavorable interaction of
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compound 21 with AChE after BChE in panel A is replaced with AChE. (C) Favorable
binding structure of compound 22 with BChE. (D) Unfavorable interaction of compound
22 with AChE after BChE in panel C is replaced with AChE. (E) Favorable binding
structure of compound 23 with BChE. (F) Unfavorable interaction of compound 23 with
AChE after BChE in panel E is replaced with AChE.
BChE selective inhibitor with other scaffolds. Although some of the solanaceous
alkaloids discovered were both highly active and selective BChE inhibitors, these
compounds possess poor water solubility and their O-glycans are known to be toxic.217
Fortunately, solanaceous alkaloids were not the only hits that we identified in this screening.
As listed below in Table 3.2 and Figure 3.6, there are seven compounds with different
scaffolds which also displayed high activity and selectivity against BChE. The inhibition
curves of these inhibitors could be found in Appendix III.

Figure 3.6 Identified BChE inhibitors with other scaffolds in this virtual screening. The
stereochemistry of compound 31 is not shown and will be discussed later in this chapter.
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Table 3.2. AChE and BChE inhibition profiles of the hit compounds through virtual
screening
Compound NSC ID
IC50 against
Inhibition against
BChE (nM)a

AChE at 10µM (%)b

31

633539

15.3 ±2.3

6.9 ±10.3c

32

658730

1391 ±185

0 ±4.9

33

612786

812.7±196.7

34.5 ±6.1

34

76443

5.6 ±5.7 (µM)

11.1 ±7.4

35

61811

386.3 ±56.7

20.1 ±6.6

36

154417

571.6 ±91.4

70.2 ±6.9

37

153594

201.2 ±29.5

57.4 ±5.7

a

Data are expressed as IC50 ±SD of single determinations obtained in triplicate. b Data are
expressed as means ± SD of single determinations obtained in triplicate. c The inhibition
of compound 31 against AChE was also detected to be at 16.1 ±5.3 %
Among

the

7

compounds,

compound

31

or

6-(3-chlorophenyl)-

1,2,3,4,6,8,9,14,14b,14c-decahydropyrido[1'',2'':3',4']imidazo[1',5':1,2]pyrido[3,4b]indole was the most potent BChE inhibitor with an IC50 of 15.3 nM. We increased the
concentration of 31 and found its inhibition against AChE was negligible even at 30 µM.
As a result, compound 31 was identified as a potent selective BChE inhibitor.

Resynthesis of 31. Since we did not have enough compound 31 for further experiments
and it was out of stock in the NCI depository, we decided to synthesize compound 31 .218219

The process was described in the previous methods section, and the synthetic scheme is

depicted below in Figure 3.3. Beside the main product, compound 31, we also obtained
another pair of enantiomers 31′, that are colored in blue in Figure 3.8.
Although compound 31 has three chiral centers, both step b and c in Figure 3.3 are
very stereoselective. The reduction step b is highly selective and will mainly yield the only
one product.218 We carried out quantum mechanics (QM) calculations using Gaussian 09
software220 on both possible products and the main product is 7.0 kcal/mol more stable than
the other one since it can form a intramolecular hydrogen bond between the NH on the
indole and the N on the piperidine ring (Figure 3.7)that has also been discussed before.218
Similarly, the final condensation step also exclusively produce only one pair of
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enantiomers.219 Steric hindrance of the other products are huge and QM calculation also
showed that red configuration of 31 in Figure 3.8 is 7.9 kcal/mol more stable than the
green pair of diastereomers.

Figure 3.7 The major (panel A,C) and minor products (panel B,D) of 31-2.
Structure elucidation of compound 31. Upon the synthesis of 31, we noticed that
Mokrosz et. al. assigned the configuration of 31 based on the NMR chemical shift of C6.
An empirical equation219 was used to justify their assignment:
𝛿𝑐 = 67.6 + 𝛴𝑙 𝐴𝑙 𝑛𝑘𝑙 + 𝑆𝑘𝑙
Since the calculated 𝛿𝑐 agreed very well with the experimental data, they assumed that
racemic 31 should have the green configurations showed in Figure 3.8. As a result, we
also used these configurations in our initial virtual screening. However, as discussed above,
we found that these purposed configurations have significantly higher energy and are
unlikely to be correct. We collected the ROESY NMR spectrum of 31 we synthesized and
it clearly indicates that the hydrogen on C6 should spatially close to the hydrogen on C14c
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instead of the one on C14b, which also agrees with our QM calculation results, thus the red
configurations in Figure 3.8 should be the correct ones.

31

31

31

31

31

31

31

31

Figure 3.8 Possible isomers of compound 31. The structure of the main products (31)
synthesized are colored in red and the minor products (31′) are colored in blue. The
structures of the main product proposed by Mokrosz et. al. are colored in green. The black
and green enantiomers were not obtained.
Chiral separation of 31 and structure identification of the active enantiomer. Since
the synthesized main product of 31 is racemic, we need to separate the enantiomers to find
out the single active enantiomer. Initially we decided to prepare the diastereoisomeric salts
using (+)-tartaric acid but failed. As a result, we used chiral HPLC to separate the racemic
compound 31 and obtained (+)-31 and (-)-31. The inhibitory activities of the separated
enantiomers against BChE were tested, and (+)-31 has an IC50 of 5.8 nM while (-)-31 has
the IC50 at 123 nM, indicating (+)-31 is the active enantiomer. However, considering that
the enantiomer we obtained has an ee (enantiomeric excess) value at 97.2% (Appendix 2),
the adjusted IC50 of (-)-31 should be even higher at 172 nM.
To investigate the structure-activity relationship of (+)-31, we cultured and solved its
single crystal from the DMSO solution. The structure is depicted in Figure 3.9. The crystal
structure of (+)-31 clearly proved that our configuration assignment of 31 was correct and
its absolute configuration should be (6S,14bR,14cS)-31. This also proved that the
empirical equation should not be solely used for structure assignment.
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Figure 3.9 Crystal structure of (6S,14bR,14cS)-31.
Table 3.3 BChE inhibition profiles of the compound 31, 31′ and the enantiomers of
compound 31 through virtual screening.

a

Compound

IC50 against BChE(nM)a

31

15.3 ±2.3

(6S,14bR,14cS)-31 ((+)-31)

5.8 ±1.1

(6R,14bS,14cR)-31 ((-)-31)

122.6 ±19.5

31′

312.4 ±126.2

Data are expressed as IC50 ±SD of single determinations obtained in triplicate.

Table 3.4 Crystallographic data for compound (+)-31
Compound
Empirical formula
Formula weight
Crystal size (mm)
Crystal system
Space group
a/Å
b/Å

(+)-31
C48H54Cl2N6OS
833.93
0.220 x 0.150 x 0.120 mm
Monoclinic
P21
9.7272(11)
24.138(3)
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Table 3.4 (continued)
c/Å
9.7459(10)
α/°
90
β/°
111.021(3)
γ/°
90
Z
2
3
V/Å
2136.0(4)
-3
Dcalcd/g·cm
1.297
T/K
90.0(2)
F(000)
884
h,k,lmax
12,31,12
R (reflections)
0.0660
Goodness-of-fit on F^2
1.089
Final R indices [I>2sigma(I)]
R1 = 0.0594, wR2 = 0.1503
R indices (all data)
R1 = 0.0620, wR2 = 0.1523
Absolute structure parameter
0.02(2)
Extinction coefficient
0.011(2)
Largest diff. peak and hole
0.744 and -0.343 e.A^-3
Prediction binding mode prediction of (6S,14bR,14cS)-31 with BChE. As the original
structure used in virtual screening was incorrect, we used the correct configuration to
analyze the binding mode of compound 31 again. Although the new binding mode has a
worse score, (6S,14bR,14cS)-31 has a reasonable binding pattern with BChE: the NH on
the indole ring could form a hydrogen bond with the carboxylate oxygen atom on D70 of
BChE, and the protonated N5 of (6S,14bR,14cS)-31 could have π-cation interaction with
W82 (Figure 3.10-A). On the other hand, it is obvious that (6R,14bS,14cR)-31 or other
enantiomers of 31 would not be able to adopt the same mode thus they will have lower
binding energies. It is also clear that with this binding mode (6S,14bR,14cS)-31 will clash
with the side chain of Y124 and Y337 in AChE, explaining the excellent selectivity of
(6S,14bR,14cS)-31. Changing different substitution groups on the phenyl ring will also
likely improve the binding affinity of (6S,14bR,14cS)-31.
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31
31

Figure 3.10 (A) Predicted binding mode of (+)-31 against BChE (B) AChE is superimposed
to BChE to see what if (+)-31 adopt the same binding mode in AChE. (+)-31 is showed in
yellow ball-and-stick models and key residues are showed in green ball-and-sticks.
Hydrogen bonds are indicated using black dashed lines and π-cation interactions are
indicated in red dashed lines. BChE and AChE is showed in cyan cartoon.

3.2.3

Conclusion

Through combined structure-based virtual screening and in vitro activity assays, we
have successfully identified selective inhibitors of human BChE. The most potent BChE
inhibitor (compound (+)-31) identified has an IC50 of 5.8 nM against BChE with no
detectable inhibition against AChE up to 30 µM. These interesting outcomes suggest that
(+)-31 may be used as a promising lead compound in our future studies of potent and highly
selective inhibitors of BChE for BChE-based drug discovery.
Notably, the extremely high selectivity of these compounds for BChE over AChE is
mainly controlled by three key residues in the active site cavity, i.e. residues Q119, A277,
and A328 in BChE versus the respective residues Y124, W286, and Y337 in AChE (all
with relatively larger side chains). Considering this structural insight, it is interesting to
focus on these key structural differences in future rational design of new, potent and highly
selective BChE inhibitors.
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3.3

DEVELOPMENT

OF
NOVEL
BUTYRYLCHOLINESTERASE
AFFINITY
CHROMATOGRAPHY RESIN CONSISTING OF A TACRINE-BASED INHIBITOR

As stated in the introduction, BChE has the potential to become a drug for various
purposes. Unfortunately, despite the high demand for BChE in academic and industrial
research laboratories, the routine purification process for BChE require many steps: an
initial 80% saturation ammonium sulfate precipitation step and extensive dialysis in order
to reduce manipulated volumes, followed by multiple affinity and ion-exchange
chromatographic steps.221 The process was time-consuming and expensive. As a result, a
huprine-based affinity chromatography resin was developed and higher than 90% purity
can be achieved in only one step.222 We were also very interested in using this resin to
purify our mutant proteins. Unfortunately, although this resin could indeed be used to
efficiently purify wild-type BChE as claimed, its affinity for our fused-BChE proteins was
undetectable. A possible explanation is that the fused part of the protein might block the
entrance of the BChE catalytic site. (Figure 3.11) Since the binding affinity of Huprine 19
used in that resin was not very high (IC50 = 0.9 µM),223 our mutations might further impair
the binding affinity of the ligand; thus, we decided to make our own version of an affinity
resin with a stronger inhibitor, tacrine, to link to the Sephadex matrix.

78

Figure 3.11 Proposed binding mode of BChE/fusion-BChE to affinity resin. The nonfusion BChE has its catalytic site expose to the ligands on the sepharose matrix while the
fusion-part of the protein might block the entrance of the catalytic site, forcing the fusion
protein to adopt alternative conformation and lowering the affinity of the resin to the
protein.
3.3.1

Methods

Synthesis of tacrine derivative ligands compound 38 and 39 and the affinity resin: All
the chemicals are purchased from Sigma-Aldrich (St. Louis, MO 63178) unless mentioned
otherwise.
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Figure 3.12 Synthesis of tacrine derivative ligands compound 38 and 39 and the affinity
resin. Reagents and conditions: (a) POCl3, reflux, 3 h; (b) phenol, KI, NH2(CH2)nNH2,
reflux, overnight. For compound 38, n=8; for compound 39, n=12. Detail information
about the organic synthesis can be found in the supporting information.
Preparation of 9-Chloro-1,2,3,4-tetrahydroacridine: In a 100 mL round bottom flask,
1.4 g (10 mmol) of anthranilic acid and 1.2 g (12 mmol) of cyclohexanone were mixed
with 2 mL of POCl3 and heated at reflux for 3 h. The solution was cooled with ice water
and basified with K2CO3 until all POCl3 was removed. The product was then filtered and
washed with brine (3 × 50 mL) to yield a yellow solid product. The product was used
directly for the next step without further purification.
Preparation of compound 38/39: To the crude product of 220 mg (1 mmol) of 9-chloro1,2,3,4-tetrahydroacridine, 3 equivalent (3 mmol) of a diamine, 5 g of phenol and 25 mg
(0.15 mmol) of KI were added and refluxed stirring with for 16 h. The mixture was cooled
down to 0˚C and then acidified to pH 2 with HCl/ether solution. The precipitant was filtered
and dissolved in 10 mL of water, basified to pH 12 with NaOH solution and extracted with
3 × 20 mL CH2Cl2. The extract was dried over anhydrous Na2SO4, have the solvent
removed under vacuum and applied to column chromatography for final purification
(CH2Cl2: MeOH = 7:3, with 1% ammonium water).
1H

NMR of compound 38 and 39: 1H NMR were recorded using a Varian 400

spectrometer in DMSO with TMS as internal reference. 38 (9-(8’-Aminooctylamino)1,2,3,4-tetrahydroacridine): 1H NMR (400 MHz, CDCl3) δ 8.03 (m, 1H), 7.83 (m, 1H),
7.61 (m, 1H), 3.61 (t, 2H), 3.02 (m, 2H), 2.85-2.75 (m, 4H), 1.92 (m, 4H), 1.68-1.32 (m,
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12H); 39 (9-(12’-Aminododecylamino)-1,2,3,4-tetrahydroacridine) δ 8.09 (m, 1H), 7.85
(m, 1H), 7.61 (m, 1H), 3.62 (t, 2H), 3.03 (m, 2H), 2.92-2.80 (m, 4H), 1.99 (m, 4H), 1.711.35 (m, 20H);
Immobilization of ligands: 1 mL of Affi-gel resin was rinsed with isopropanol and dried
to powder. A 100 mg portion of ligands (compound 38 or 39) were dissolved in 10 mL of
methanol and mixed with the resin powder. The mixture was shaken at 4°C for 24 h. The
coupled resin is loaded on to a column and washed extensively with methanol (50 mL) and
the washing buffer (20mM KnPO4, 1mM EDTA, 0.25M NaCl, pH=7.0) for 150 mL until
no ligand is washed out (under A280 absorption for detection) and is ready for use.
Purification of BChE with affinity chromatography resin: With 1mL of the prepared
resin loaded, 8mL of the enzyme solution was loaded on to the column and flowed through
directly in less than 30 minutes. The column was then washed using the above mentioned
washing buffer for 50mL. The washing buffer was collected and tested for BChE enzyme
activity. The column was eluted using 100mL elution buffer (20mM KnPO4, 1mM EDTA,
0.1M NaCl, 0.5M tetramethylammonium chloride (TMAC), pH=7.0). The elution buffer
was dialysed using washing buffer to make the theorectical TMAC concentration less than
100 pM. The solution is concentrated for further activity tests or other uses.
BChE activity tests: same method as described in the previous section was used to
determine the activity of BChE proteins.

3.3.2

Results

As expected, the new tacrine-based resin with compound 38 as the ligand showed good
binding affinity towards both non-fusion and fusion BChE proteins:
Table 3.5 Binding affinity of compound 38-coupled Affi-gel-10 affinity resin.
Protein type

Binding Capacity
(µg/mL resin)

Non-fusion BChE

660

Fc-fusion BChE

118

HSA-fusion BChE

155
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We also tested the resin with compound 39 as the ligand and it has very similar binding
affinity to the compound 38 based resin (115 µg/mL towards Fc-fusion BChE compared
to 118 µg/mL for compound 38).

Figure 3.13 SDS-page gel image of unpurified and purified BChE proteins.
3.3.3

Discussion and conclusion

As the data showed above, our newly prepared tacrine-based showed good binding
affinity to both non-fusion and fusion BChE proteins. The binding capacity to the fusion
proteins are weaker than the non-fusion ones that was expected as the entrance of the ligand
binding site are hindered by the fusion part of the protein. However, the binding affinity of
the tacrine-based resin is sufficient to purify fusion BChE proteins that is a huge
improvement compared to the huprine-based resin. Using the new resin for one-step
purification provided fusion BChE proteins with good purity. Combining the regular
purification methods like cation exchange with this affinity resin purification methods, we
obtained the target fusion proteins at very high purity. In conclusion, the new tacrine-based
resin provided an efficient purification method for fusion BChE proteins.
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CHAPTER 4. CONCLUDING REMARKS AND FUTURE PLAN

In the previous chapters, I have demonstrated how our new drug discovery strategies
were developed and applied to help us identify drug candidates in two different projects.
Specifically, in mPGES-1 inhibitor project we:
• Discovered the alternative conformation of mPGES-1 in MD simulation, which
partially explained some interesting experimental properties of mPGES-1 like why the
Apo-form cannot be crystallized or why mPGES-1 can transfer from an isomerase into
a reductase when some residues are mutated.
• Performed virtual screening using molecular docking and the following MM-PBSA
calculations based on the novel alternative conformation and a few mPGES-1
inhibitors with novel acting mechanism were identified. Among them include FDA
approved drug lapatinib, which can be repurposed as an anti-inflammatory drug.
• Performed clinical trial data mining. With a PK data analysis, the in vivo lapatinib
concentration was proved to be above the effective dose to inhibit mPGES-1. With a
meta-analysis on the pain data across 18 phase II or III trials, lapatinib was proved to
be effective against various types of pain in cancer patients.

In the BChE inhibitor project, we:
•

Based on the structural differences between AChE and BChE, we performed
virtual screening and discovered a few BChE inhibitors, with both high selectivity
and activity. The best compound (+)-31 has an IC50 against BChE at only 5.8 nM
while showed no inhibition against AChE at 50 μM. We also corrected the
configuration of compound 31 based on both theoretical computation and
experimental data.
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•

Developed a tacrine-based affinity resin, which has good binding affinity towards
fusion BChE proteins. With this new affinity resin, the purification of fusion BChE
proteins could be more efficient.

Although some discoveries were made, we still need to further advance our
investigations based on current results:
•

We need to prove the analgesic efficacy of lapatinib in non-cancer patients.
Theoretically the analgesic effects of lapatinib we have discovered have no
relationship with cancer. However, a dedicated clinical trial will still be necessary
to prove the analgesic effects in non-cancer patients.

•

The molecular structure of lapatinib can be modified to further improve its binding
affinity towards mPGES-1 while making it losing inhibition against EGFR/HER2
to reduce its adverse effects.

•

Further animal experiments are necessary to evaluate the in vivo activities of
compound 31.
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APPENDICES

[APPENDIX 1. SUPPLEMENTAL INFORMATION FOR META-ANALYSIS]
Table A. 1 Data of various types of pain reported as serious side-effects in the clinical trials
listed in Table 2.6. Only data from the six types of pain discussed in the “Major Pain Events”
section are listed here.

Clinical trial
No.
NCT00558103
NCT00374322
NCT00553358
NCT00490139
NCT00073528
NCT00390455
NCT00075270
NCT00770809

Positive counts in
experimental group
1
0
0
2
0
2
1
0

Clinical trial
No.
NCT00486954
NCT00490139
NCT00073528
NCT00390455
NCT00075270
NCT00680901

Positive counts in
experimental group
1
1
2
0
2
0

Clinical trial
No.
NCT00073528
NCT00390455
NCT00374322
NCT00680901
NCT00770809

Positive counts in
experimental group
1
0
0
0
0

Headache
Negative counts in
experimental group
37
1573
152
2059
654
139
292
115
Arthralgia
Negative counts in
experimental group
130
2060
652
141
291
270
Bone pain
Negative counts in
experimental group
651
141
1573
270
115
Myalgia
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Positive counts
in control group
0
1
1
1
2
0
0
1

Negative counts
in control group
13
1573
148
2075
622
137
286
114

Positive counts
in control group
0
0
5
1
0
1

Negative counts
in control group
129
2076
619
136
286
266

Positive counts
in control group
1
1
1
1
1

Negative counts
in control group
623
136
1573
266
114

Clinical trial
No.
NCT00490139
NCT00075270
NCT00770809
NCT00374322
NCT00424255

Positive counts in
experimental group
2
0
3
0
1

Clinical trial
No.
NCT00073528
NCT00075270

Positive counts in
experimental group
1
3

Clinical trial
No.
NCT00073528

Positive counts in
experimental group
1

Table A.1 (continued)
Negative counts in
Positive counts
experimental group in control group
2059
0
293
1
112
2
1573
1
348
1
Pain in extremity
Negative counts in
Positive counts
experimental group in control group
653
0
290
0
Musculoskeletal pain
Negative counts in
Positive counts
experimental group in control group
653
0

Figure A1. 1 Funnel plot for headache analysis
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Negative counts
in control group
2076
285
113
1573
335
Negative counts
in control group
624
286
Negative counts
in control group
624

Figure A1. 2 Funnel plot for bone pain

Figure A1. 3 Funnel plot for arthralgia
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Figure A1. 4 Funnel plot for myalgia

Figure A1. 5 Funnel plot for pain in extremity
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Figure A1. 6 Funnel plot for musculoskeletal pain

Figure A1. 7 Funnel plot for the overall effect analysis
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Figure A1. 8 Funnel plot of lapatinib on myalgia, when NCT00075270, NCT00486954 and
NCT00281658 were excluded.

Figure A1. 9 Effect of lapatinib on myalgia, when NCT00075270, NCT00486954 and
NCT00281658 were excluded.
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Figure A1. 10 Effect of lapatinib on headache, when NCT00075270, NCT00486954 and
NCT00281658 were excluded.
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Figure A1. 11 Effect of lapatinib on bone pain, when NCT00075270, NCT00486954 and
NCT00281658 were excluded.

Figure A1. 12 Effect of lapatinib on arthralgia, when NCT00075270, NCT00486954 and
NCT00281658 were excluded.
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Figure A1. 13 Effect of lapatinib on pain in extremity, when NCT00075270,
NCT00486954 and NCT00281658 were excluded.

Figure A1. 14 Effect of lapatinib on musculoskeletal pain, when NCT00075270,
NCT00486954 and NCT00281658 were excluded.
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[APPENDIX 2. HPLC AND NMR DATA FOR COMPOUND 31 AND
DERIVATIVES]

Racemic (±)-31.
8.473

0.030

3.438

2.630

0.010
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AU

0.020

0.000

1.00

2.00

3.00

4.00

5.00
Minutes

6.00

7.00

6.00

7.00

8.00

9.00

10.00

9.00

10.00

(+)-31, retention time = 8.473min. ee = 97.4%
7.675

0.040

4.245

0.010

8.491

0.020

3.435
3.597

AU

0.030

0.000

1.00

2.00

3.00

4.00

(-)-31, retention time = 7.675min. ee = 97.2%
Figure A2. 1 HPLC of 31

5.00
Minutes

8.00

Figure A2. 2 1HNMR of 31

Figure A2. 3 13C NMR of 31
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Figure A2. 4 COSY of 31

Figure A2. 5 HSQC of 31
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Figure A2. 6 HMBC of 31

Figure A2. 7 ROESY of 31
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Figure A2. 8 1H NMR of 31′

Figure A2. 9 COSY of 31′
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[APPENDIX 3. INHIBITION CURVES OF VARIOUS BCHE INHIBITORS]
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[APPENDIX 4. LIST OF ABBREVIATIONS]
ACh

acetylcholine

AChE

acetylcholinesterase

AD

Alzheimer’s disease

ATC

acetylthiocholine

ATP

adenosine triphosphate

BChE

butyrylcholinesterase

CADD

computer-aided drug design

CapeOx

capecitabine and oxaliplatin

ChE

cholinesterase

CI

confidence interval

COX

cyclooxygenase

CryoEM

cryogenic electron microscope

DMF

dimethylformamide

DMSO

dimethylsulfoxide

DOPC

1,2-dioleoyl-sn-glycero-3-phosphocholine

DREAM-in-

drug repurposing effort applying integrated modeling-in vitro/vivo-

CDM

clinical data mining

DTNB

5,5'-dithiobis-(2-nitrobenzoic acid)

EDTA

ethylenediaminetetraacetic acid

ELISA

enzyme-linked immunosorbent assay

FDA

Food and Drug Administration

FLAP

5-lipoxygenase activating protein

GSH

glutathione

GSSG

glutathione disulfide

HPLC

high performance liquid chromatography

h

hour

HSA

human serum albumin

IC50

half maximal inhibitory concentration
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LeuT

bacterial leucine transporter

MAPEG

membrane-associated proteins in eicosanoid and GSH metabolism

MD

molecular dynamics

mGST1-L1

microsomal glutathione transferase 1 like protein 1

MM

molecular mechanics

mM

millimole

MM-PBSA

molecular mechanics Poisson-Boltzmann surface area

mPGES-1

microsomal prostaglandin E2 synthase 1

NCI

national cancer institute

nM

nanomole

NMR

nuclear magnetic resonance

ns

nanosecond

NSAID

Nonsteroidal anti-inflammatory drug

OR

odds ratio

OUDs

opioid use disorders

PGH2

prostaglandin H2

PMF

potential of mean force

ps

picosecond

QM

quantum mechanics

RMSD

root-mean-square deviation

SAR

structure-activity relationship

SDS

sodium dodecyl sulfate

TMAC

tetramethylammonium chloride

TMD

targeted molecular dynamics

μM

micromole
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[APPENDIX 5. COMPOUNDS WITH IN VITRO ACTIVITY TESTED IN THIS
DISSERTATION]
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M.; Živin, M.; Podkowa, A., The magic of crystal structure-based inhibitor optimization:
development of a butyrylcholinesterase inhibitor with picomolar affinity and in vivo
activity. Journal of medicinal chemistry 2017, 61 (1), 119-139.
183. Dighe, S. N.; Deora, G. S.; De la Mora, E.; Nachon, F.; Chan, S.; Parat, M.-O.;
Brazzolotto, X.; Ross, B. P., Discovery and Structure–Activity Relationships of a Highly
Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening. Journal of
medicinal chemistry 2016, 59 (16), 7683-7689.
184. Sakkiah, S.; Lee, K. W., Pharmacophore-based virtual screening and density
functional theory approach to identifying novel butyrylcholinesterase inhibitors. Acta
Pharmacologica Sinica 2012, 33 (7), 964.
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